



Disclaimer

The following report(s) provides findings from an FDA-initiated query using its Mini-Sentinel pilot. While Mini-Sentinel queries may be undertaken to assess potential medical product safety risks, they may also be initiated for various other reasons. Some examples include determining a rate or count of an identified health outcome of interest, examining medical product use, exploring the feasibility of future, more detailed analyses within Mini-Sentinel, and seeking to better understand the capabilities of the Mini-Sentinel pilot.

Data obtained through Mini-Sentinel are intended to complement other types of evidence such as preclinical studies, clinical trials, postmarket studies, and adverse event reports, all of which are used by FDA to inform regulatory decisions regarding medical product safety. The information contained in this report is provided as part of FDA's commitment to place knowledge acquired from the Mini-Sentinel pilot in the public domain as soon as possible. Any public health actions taken by FDA regarding products involved in Mini-Sentinel queries will continue to be communicated through existing channels.

FDA wants to emphasize that the fact that FDA has initiated a query involving a medical product and is reporting findings related to that query does not mean that FDA is suggesting health care practitioners should change their prescribing practices for the medical product or that patients taking the medical product should stop using it. Patients who have questions about the use of an identified medical product should contact their health care practitioners.

The following report contains a description of the request, request specifications, and results from the modular program run(s).

If you are using a web page screen reader and are unable to access this document, please contact the Mini-Sentinel Operations Center for assistance at info@sentinelssystem.org.

Overview for Request to16_cap_mpl1r_wp022_nsdp_v01, Report 1 of 2

Request ID: to16_cap_mpl1r_wp022_nsdp_v01. This is Report 1 of 2.

Query Description: The Opioid Analgesics Prescribing Trends Workgroup has requested execution of the Cohort Identification and Descriptive Analysis (CIDA) tool, version 2.0.7, to find estimates of the percentage of extended-release and long-acting (ER/LA) opioid analgesics users who have a drug screen in the month prior to opioid use or in the six months after opioid use. The query was run against the Mini-Sentinel Distributed Database (MSDD) for the time period of January 1, 2009 to December 31, 2013. The request was distributed to 15 Data Partners on July 29, 2015. This report contains results for ER/LA opioid analgesics. Report 2 contains results for ER oxycodone.

Study Design: This request was designed to identify exposures with and without drug screens in the month prior or within six months after opioid initiation. The number of exposure episodes in the MSDD was calculated overall and was stratified by age group, sex, and year.

Exposures of Interest: The exposures of interest were extended-release and long-acting (ER/LA) opioid analgesics and extended-release oxycodone. Please refer to Appendix A for a list of drugs.

Cohort Eligibility Criteria: Those included in the cohort were required to be continuously enrolled in plans with both medical and drug coverage for at least six months (183 days) before their exposure date, during which gaps in coverage of up to 45 days were allowed. The following age groups were included in the cohort: 0-11, 12-17, 18-24, 25-34, 35-44, 45-54, and 55-64 years. The cohort includes patients who used ER/LA opioid analgesics for at least one day, with an outpatient pharmacy dispensing days supplied of at least one day. All qualifying incident exposure episodes per patient that occurred between January 1, 2009 and December 31, 2013 were examined. See Appendix B for a list of procedure codes in this request. Individuals with an opioid poisoning diagnosis within six months (183 days) prior to the date of exposure were excluded from the cohort (please see Appendix C for specific codes). Individuals were also required to have no evidence of any ER/LA opioid (see Appendix A for specific drugs) in the six months (183 days) prior to the dispensing of the drug of interest.

Sensitivity Analyses: Three sensitivity analyses were conducted for the cohort and each cohort subset described above:

1) The first sensitivity analysis was designed to capture long-term and chronic opioid users of ER/LA opioid analgesics. Chronic use is defined as an exposure episode with at least 12 weeks (84 days) supplied for ER/LA opioid analgesics outpatient pharmacy dispensings. Exposure episodes were created with the following methods:

- a. Multiple drug dispensings were considered part of the same exposure episode if the end of the days supplied for the first dispensing and the next dispensing were less than 10 days apart.
- b. Multiple drug dispensings with the same generic name and dose occurring on the same day used the maximum days supplied value and added together the amount supplied values of each dispensing.
- c. If two dispensings with the same generic name and dose overlapped, any overlap of supply between dispensing was corrected by pushing overlapping days supplied forward.

2) The second sensitivity analysis was designed to examine a less strict definition of cohort eligibility, in which individuals were required to be continuously enrolled in plans with both medical and drug coverage for at least three months (90 days) before their dispensing date, during which gaps in coverage of up to 45 days were allowed. Individuals were also required to have no evidence of any ER/LA opioid in the three months (90 days) prior to the dispensing of the drug of interest. In addition to the main analysis, this sensitivity analysis was combined with the first sensitivity analysis to apply a less strict cohort.

3) The third sensitivity analysis was designed to stratify by evidence of an immediate release (IR) opioid prescription within two months to one day before the date of exposure (please see Appendix C for specific drugs). Due to programmatic restrictions, IR opioid use was set up as an exclusion; however, the output has been used to calculate the number of users who did have an IR opioid prescription within two months prior to exposure, which is displayed in Tables 1-4 (complete results for each cohort are displayed in the Appendices for Tables 1-4). In addition to the main analysis, this sensitivity analysis was combined with all other sensitivity analyses.

Please see Appendix D for the specifications of parameters used in the analyses for this request.

Limitations: Algorithms to define exposures, exclusion criteria, and outcomes are imperfect and, therefore, may be misclassified.

Notes: Please contact the Sentinel Operations Center Query Fulfillment Team (qf@sentinelssystem.org) for questions and to provide comments/suggestions for future enhancements to this document.

Table of Contents

<u>Glossary</u>	List of Terms Found in this Report and their Definitions
<u>Table 1</u>	Percentage of New Extended-Release and Long-Acting (ER/LA) Opioid Analgesics Users and Episodes with Drug Screens in the Mini-Sentinel Distributed Database (MSDD) between January 1, 2009 and December 31, 2013, by Incidence Assessment Period/Enrollment Requirement, Minimum Days Supplied, and Evidence of Prior Immediate Release (IR) Opioid Use
<u>Appendix Table1</u>	Summary of Extended-Release and Long-Acting (ER/LA) Opioid Analgesics Use and Drug Screens in the Mini-Sentinel Distributed Database (MSDD) between January 1, 2009 and December 31, 2013, by Incidence Assessment Period/Enrollment Requirement, Minimum Days Supplied, Immediate Release (IR) Exclusion Requirement, and Drug Screen Inclusion Requirement
<u>Table 2</u>	Percentage of New Extended-Release and Long-Acting (ER/LA) Opioid Analgesics Users and Episodes with Drug Screens in the Mini-Sentinel Distributed Database (MSDD) between January 1, 2009 and December 31, 2013, by Incidence Assessment Period/Enrollment Requirement, Minimum Days Supplied, Evidence of Prior Immediate Release (IR) Opioid Use, and Age Group
<u>Appendix Table2</u>	Summary of Extended-Release and Long-Acting (ER/LA) Opioid Analgesics Use and Drug Screens in the Mini-Sentinel Distributed Database (MSDD) between January 1, 2009 and December 31, 2013, by Incidence Assessment Period/Enrollment Requirement, Minimum Days Supplied, Immediate Release (IR) Exclusion Requirement, Drug Screen Inclusion Requirement, and Age Group
<u>Table 3</u>	Percentage of New Extended-Release and Long-Acting (ER/LA) Opioid Analgesics Users and Episodes with Drug Screens in the Mini-Sentinel Distributed Database (MSDD) between January 1, 2009 and December 31, 2013, by Incidence Assessment Period/Enrollment Requirement, Minimum Days Supplied, Evidence of Prior Immediate Release (IR) Opioid Use, and Sex
<u>Appendix Table3</u>	Summary of Extended-Release and Long-Acting (ER/LA) Opioid Analgesics Use and Drug Screens in the Mini-Sentinel Distributed Database (MSDD) between January 1, 2009 and December 31, 2013, by Incidence Assessment Period/Enrollment Requirement, Minimum Days Supplied, Immediate Release (IR) Exclusion Requirement, Drug Screen Inclusion Requirement, and Sex
<u>Table 4</u>	Percentage of New Extended-Release and Long-Acting (ER/LA) Opioid Analgesics Users and Episodes with Drug Screens in the Mini-Sentinel Distributed Database (MSDD) between January 1, 2009 and December 31, 2013, by Incidence Assessment Period/Enrollment Requirement, Minimum Days Supplied, Evidence of Prior Immediate Release (IR) Opioid Use, and Year
<u>Appendix A</u>	List of Drugs used for Exposures in this Request
<u>Appendix B</u>	List of Healthcare Common Procedure Coding System (HCPCS) and Current Procedural Terminology, Fourth Revision (CPT-4) Procedure Codes used for Drug Screens in this Request
<u>Appendix C1</u>	List of International Classification of Diseases, Ninth Edition, Clinical Modification (ICD-9-CM) Diagnosis Codes used for Exclusions in this Request
<u>Appendix C2</u>	List of Drugs used for Inclusions/Exclusions in this Request
<u>Appendix D</u>	Specifications Document Defining Parameters used in this Request
<u>Appendix E</u>	List of Dates of Available Data for Each Data Partner as of Request Send Date (July 29, 2015)

Glossary of Terms for Analyses Using Cohort Identification and Descriptive Analysis (CIDA) Tool*

- Amount Supplied** - number of units (pills, tablets, vials) dispensed. Net amount per NDC per dispensing. This is equivalent to the
- Blackout Period** - number of days at the beginning of a treatment episode that events are to be ignored. If an event occurs during the blackout period, the episode is excluded.
- Care Setting** - type of medical encounter or facility where the exposure, event, or condition code was recorded. Possible care settings include: Inpatient Hospital Stay (IP), Non-Acute Institutional Stay (IS), Emergency Department (ED), Ambulatory Visit (AV), and Other Ambulatory Visit (OA). For laboratory results, possible care settings include: Emergency department (E), Home (H), Inpatient (I), Outpatient (O), or Unknown or Missing (U). Along with the Principal Diagnosis Indicator, forms the Care Setting/PDX parameter.
- Cohort Definition (drug/exposure)**- indicates how the cohort will be defined: (1) 01: Cohort includes only the first valid incident treatment episode during the query period; (2) 02: Cohort includes all valid incident treatment episodes during the query period; (3) 03: Cohort includes all valid incident treatment episodes during the query period until an event occurs.
- Days Supplied** - number of days supplied for all dispensings in qualifying treatment episodes.
- Enrollment Gap** - number of days allowed between two consecutive enrollment periods without breaking a "continuously enrolled"
- Episodes** - treatment episodes; length of episode is determined by days supplied in one dispensing or consecutive dispensings bridged
- Episode Gap** - number of days allowed between two (or more) consecutive exposures (dispensings/procedures) to be considered the
- Event Deduplication** - specifies how events are counted by the MP algorithm: (0) 0: Counts all occurrences of an HOI during an exposure episode; (1) 1: de-duplicates occurrences of the same HOI code and code type on the same day; (2) 2: de-duplicates occurrences of the same HOI group on the same day (e.g., de-duplicates at the group level).
- Exposure Extension Period** - number of days post treatment period in which the outcomes/events are counted for a treatment
- Exposure Episode Length** - number of days after exposure initiation that is considered "exposed time."
- Lookback Period (pre-existing condition)** - number of days wherein a member is required to have evidence of pre-existing condition (diagnosis/procedure/drug dispensing).
- Minimum Days Supplied** - specifies a minimum number of days in length of the days supplied for the episode to be considered.
- Minimum Episode Duration** - specifies a minimum number of days in length of the episode for it to be considered.
- Principal Diagnosis (PDX)** - diagnosis or condition established to be chiefly responsible for admission of the patient to the hospital. 'P' = principal diagnosis, 'S' = secondary diagnosis, 'X' = unspecified diagnosis, '.' = blank. Along with the Care Setting values, forms the
- Query Period** - period in which the modular program looks for exposures and outcomes of interest.
- Treatment Episode Truncation Indicator** - indicates whether observation of the incident query code during follow-up requires truncation of valid treatment episodes. A value of Y indicates that the treatment episodes should be truncated at the first occurrence of an incident query code. A value of N indicates that the treatment episodes should not be truncated at the occurrence of the
- Users** - number of members with exposure during the query period. Member must have no evidence of exposure(s) of interest (defined by incidence criteria) in the prior washout period. A user may only be counted once in a query period.
- Washout Period (drug/exposure)**** - number of days a user is required to have no evidence of prior exposure (drug dispensing/procedure) and continuous drug and medical coverage prior to an incident treatment episode.
- Washout Period (event/outcome)**** - number of days a user is required to have no evidence of a prior event (procedure/diagnosis) and continuous drug and medical coverage prior to an incident treatment episode.
- Years at Risk** - number of days supplied plus any episode gaps and exposure extension periods all divided by 365.25.

*all terms may not be used in this report

**incident treatment episodes must be incident to both the exposure and the event

Table 1: Percentage of New Extended-Release and Long-Acting (ER/LA) Opioid Analgesics Users and Episodes with Drug Screens in the Mini-Sentinel Distributed Database (MSDD) between January 1, 2009 and December 31, 2013, by Incidence Assessment Period/Enrollment Requirement, Minimum Days Supplied, and Evidence of Prior Immediate Release (IR) Opioid Use

	New Users	Percentage of New Users with Drug Screen	New Episodes	Percentage of New Episodes with Drug
All Incident ER/LA Opioid Analgesics Use				
183-day Incidence Assessment Period/Enrollment Requirement				
<i>Minimum Days Supplied = 1 Day</i>				
All	479,820	N/A	522,241	N/A
Drug Screen in the Prior 30 Days	48,954	10.2%	50,565	9.7%
Drug Screen in the Following 183 Days	84,485	17.6%	89,379	17.1%
<i>Minimum Days Supplied = 84 Days</i>				
All	116,690	N/A	119,783	N/A
Drug Screen in the Prior 30 Days	21,176	18.1%	21,397	17.9%
Drug Screen in the Following 183 Days	38,793	33.2%	39,490	33.0%
90-day Incidence Assessment Period/Enrollment Requirement				
<i>Minimum Days Supplied = 1 Day</i>				
All	539,129	N/A	624,468	N/A
Drug Screen in the Prior 30 Days	59,161	11.0%	62,693	10.0%
Drug Screen in the Following 183 Days	101,154	18.8%	112,132	18.0%
<i>Minimum Days Supplied = 84 Days</i>				
All	141,404	N/A	148,737	N/A
Drug Screen in the Prior 30 Days	26,129	18.5%	26,671	17.9%
Drug Screen in the Following 183 Days	47,920	33.9%	49,572	33.3%
Incident ER/LA Opioid Analgesics Use with an IR Opioid Prescription in the Prior 60 Days				
183-day Incidence Assessment Period/Enrollment Requirement				
<i>Minimum Days Supplied = 1 Day</i>				
All	339,731	N/A	376,440	N/A
Drug Screen in the Prior 30 Days	43,021	12.7%	44,577	11.8%
Drug Screen in the Following 183 Days	73,484	21.6%	78,188	20.8%
<i>Minimum Days Supplied = 84 Days</i>				
All	101,592	N/A	104,529	N/A
Drug Screen in the Prior 30 Days	19,204	18.9%	19,420	18.6%
Drug Screen in the Following 183 Days	34,768	34.2%	35,449	33.9%
90-day Incidence Assessment Period/Enrollment Requirement				
<i>Minimum Days Supplied = 1 Day</i>				
All	375,903	N/A	447,779	N/A
Drug Screen in the Prior 30 Days	51,210	13.6%	54,570	12.2%
Drug Screen in the Following 183 Days	86,181	22.9%	96,561	21.6%
<i>Minimum Days Supplied = 84 Days</i>				
All	120,281	N/A	126,972	N/A
Drug Screen in the Prior 30 Days	23,336	19.4%	23,859	18.8%
Drug Screen in the Following 183 Days	42,136	35.0%	43,723	34.4%

Appendix for Table 1: Summary of Extended-Release and Long-Acting (ER/LA) Opioid Analgesics Use and Drug Screens in the Mini-Sentinel Distributed Database (MSDD) between January 1, 2009 and December 31, 2013, by Incidence Assessment Period/Enrollment Requirement, Minimum Days Supplied, Immediate Release (IR) Exclusion Requirement, and Drug Screen Inclusion Requirement

	New Users	New Episodes	Dispensings	Days Supplied	Amount Supplied	Eligible Members	Member-Years	New Users/1K Eligible	Days Supplied/ User	Dispensings/ User	Days Supplied/D ispending
183-day Incidence Assessment Period/Enrollment Requirement (No IR opioid use exclusion requirement)											
<i>Minimum Days Supplied = 1 Day</i>											
All	479,820	522,241	2,033,692	53,245,362	111,507,383	74,714,981	152,248,086.5	6.42	110.97	4.24	26.18
Drug Screen in the Prior 30 Days	48,954	50,565	312,987	8,571,680	17,674,863	N/A	N/A	N/A	175.10	6.39	27.39
Drug Screen in the Following 183 Days	84,485	89,379	581,896	15,942,788	33,786,689	N/A	N/A	N/A	188.71	6.89	27.40
<i>Minimum Days Supplied = 84 Days</i>											
All	116,690	119,783	1,484,410	42,082,130	91,506,772	70,340,867	140,796,647.4	1.66	360.63	12.72	28.35
Drug Screen in the Prior 30 Days	21,176	21,397	269,332	7,532,410	15,866,183	N/A	N/A	N/A	355.71	12.72	27.97
Drug Screen in the Following 183 Days	38,793	39,490	506,695	14,165,610	30,608,610	N/A	N/A	N/A	365.16	13.06	27.96
90-day Incidence Assessment Period/Enrollment Requirement (No IR opioid use exclusion requirement)											
<i>Minimum Days Supplied = 1 Day</i>											
All	539,129	624,468	2,477,938	65,342,153	139,327,603	81,060,908	164,985,543.2	6.65	121.20	4.60	26.37
Drug Screen in the Prior 30 Days	59,161	62,693	388,883	10,653,311	22,294,524	N/A	N/A	N/A	180.07	6.57	27.39
Drug Screen in the Following 183 Days	101,154	112,132	725,115	19,870,984	42,751,590	N/A	N/A	N/A	196.44	7.17	27.40
<i>Minimum Days Supplied = 84 Days</i>											
All	141,404	148,737	1,827,957	51,879,444	114,616,416	75,734,629	152,382,061.8	1.87	366.89	12.93	28.38
Drug Screen in the Prior 30 Days	26,129	26,671	334,769	9,364,938	20,016,243	N/A	N/A	N/A	358.41	12.81	27.97
Drug Screen in the Following 183 Days	47,920	49,572	630,852	17,631,628	38,650,333	N/A	N/A	N/A	367.94	13.16	27.95
183-day Incidence Assessment Period/Enrollment Requirement (IR opioid use exclusion requirement)											
<i>Minimum Days Supplied = 1 Day</i>											
All	140,089	145,801	337,318	7,718,613	18,485,342	74,037,424	144,473,502.9	1.89	55.10	2.41	22.88
Drug Screen in the Prior 30 Days	5,933	5,988	30,240	800,691	2,046,515	N/A	N/A	N/A	134.96	5.10	26.48
Drug Screen in the Following 183 Days	11,001	11,191	62,530	1,667,970	4,436,099	N/A	N/A	N/A	151.62	5.68	26.67
<i>Minimum Days Supplied = 84 Days</i>											
All	15,098	15,254	176,761	5,008,410	13,128,347	69,669,024	133,629,038.3	0.22	331.73	11.71	28.33
Drug Screen in the Prior 30 Days	1,972	1,977	24,495	672,989	1,792,699	N/A	N/A	N/A	341.27	12.42	27.47
Drug Screen in the Following 183 Days	4,025	4,041	51,991	1,437,582	3,948,798	N/A	N/A	N/A	357.16	12.92	27.65
90-day Incidence Assessment Period/Enrollment Requirement (IR opioid use exclusion requirement)											
<i>Minimum Days Supplied = 1 Day</i>											
All	163,226	176,689	441,892	10,541,883	26,332,271	80,356,374	156,577,036.2	2.03	64.58	2.71	23.86
Drug Screen in the Prior 30 Days	7,951	8,123	42,571	1,140,599	3,051,850	N/A	N/A	N/A	143.45	5.35	26.79
Drug Screen in the Following 183 Days	14,973	15,571	89,095	2,395,854	6,536,115	N/A	N/A	N/A	160.01	5.95	26.89
<i>Minimum Days Supplied = 84 Days</i>											
All	21,123	21,765	250,411	7,152,831	19,320,159	75,057,459	144,642,546.7	0.28	338.63	11.85	28.56
Drug Screen in the Prior 30 Days	2,793	2,812	34,907	967,734	2,695,857	N/A	N/A	N/A	346.49	12.50	27.72
Drug Screen in the Following 183 Days	5,784	5,849	74,787	2,074,520	5,817,518	N/A	N/A	N/A	358.67	12.93	27.74

Table 2: Percentage of New Extended-Release and Long-Acting (ER/LA) Opioid Analgesics Users and Episodes with Drug Screens in the Mini-Sentinel Distributed Database (MSDD) between January 1, 2009 and December 31, 2013, by Incidence Assessment Period/Enrollment Requirement, Minimum Days Supplied, Evidence of Prior Immediate Release (IR) Opioid Use, and Age Group

	Percentage of New Users		New Episodes	Percentage of New
	New Users	with Drug Screen		Episodes with Drug
				Screen
All Incident ER/LA Opioid Analgesics Use				
183-day Incidence Assessment Period/Enrollment Requirement				
<i>Minimum Days Supplied = 1 Day</i>				
All				
00-11 Years	1,136	N/A	1,185	N/A
12-17 Years	6,166	N/A	6,432	N/A
18-24 Years	19,925	N/A	20,983	N/A
25-34 Years	52,211	N/A	55,459	N/A
35-44 Years	88,999	N/A	95,608	N/A
45-54 Years	151,670	N/A	163,925	N/A
55-64 Years	165,318	N/A	178,649	N/A
Drug Screen in the Prior 30 Days				
00-11 Years	13	1.1%	13	1.1%
12-17 Years	104	1.7%	105	1.6%
18-24 Years	1,841	9.2%	1,873	8.9%
25-34 Years	7,791	14.9%	7,989	14.4%
35-44 Years	12,038	13.5%	12,368	12.9%
45-54 Years	16,036	10.6%	16,529	10.1%
55-64 Years	11,362	6.9%	11,688	6.5%
Drug Screen in the Following 183 Days				
00-11 Years	50	4.4%	50	4.2%
12-17 Years	254	4.1%	257	4.0%
18-24 Years	3,346	16.8%	3,481	16.6%
25-34 Years	13,116	25.1%	13,748	24.8%
35-44 Years	20,249	22.8%	21,265	22.2%
45-54 Years	27,648	18.2%	29,090	17.7%
55-64 Years	20,464	12.4%	21,488	12.0%
<i>Minimum Days Supplied = 84 Days</i>				
All				
00-11 Years	65	N/A	65	N/A
12-17 Years	240	N/A	240	N/A
18-24 Years	2,797	N/A	2,836	N/A
25-34 Years	13,534	N/A	13,812	N/A
35-44 Years	24,421	N/A	24,975	N/A
45-54 Years	39,712	N/A	40,638	N/A
55-64 Years	36,467	N/A	37,217	N/A
Drug Screen in the Prior 30 Days				
00-11 Years	1	1.5%	1	1.5%
12-17 Years	25	10.4%	25	10.4%
18-24 Years	567	20.3%	568	20.0%
25-34 Years	3,157	23.3%	3,187	23.1%
35-44 Years	5,428	22.2%	5,466	21.9%
45-54 Years	7,183	18.1%	7,258	17.9%
55-64 Years	4,849	13.3%	4,892	13.1%

Table 2: Percentage of New Extended-Release and Long-Acting (ER/LA) Opioid Analgesics Users and Episodes with Drug Screens in the Mini-Sentinel Distributed Database (MSDD) between January 1, 2009 and December 31, 2013, by Incidence Assessment Period/Enrollment Requirement, Minimum Days Supplied, Evidence of Prior Immediate Release (IR) Opioid Use, and Age Group

	Percentage of New Users		New Episodes	Percentage of New Episodes with Drug Screen
	New Users	with Drug Screen		
Drug Screen in the Following 183 Days				
00-11 Years	5	7.7%	5	7.7%
12-17 Years	52	21.7%	52	21.7%
18-24 Years	1,133	40.5%	1,142	40.3%
25-34 Years	5,887	43.5%	5,977	43.3%
35-44 Years	9,734	39.9%	9,880	39.6%
45-54 Years	13,024	32.8%	13,236	32.6%
55-64 Years	9,067	24.9%	9,198	24.7%
All Incident ER/LA Opioid Analgesics Use				
90-day Incidence Assessment Period/Enrollment Requirement				
<i>Minimum Days Supplied = 1 Day</i>				
All				
00-11 Years	1,380	N/A	1,471	N/A
12-17 Years	6,604	N/A	7,099	N/A
18-24 Years	22,389	N/A	24,489	N/A
25-34 Years	60,676	N/A	67,752	N/A
35-44 Years	101,923	N/A	115,849	N/A
45-54 Years	171,508	N/A	197,231	N/A
55-64 Years	183,104	N/A	210,577	N/A
Drug Screen in the Prior 30 Days				
00-11 Years	13	0.9%	13	0.9%
12-17 Years	111	1.7%	114	1.6%
18-24 Years	2,151	9.6%	2,238	9.1%
25-34 Years	9,477	15.6%	9,934	14.7%
35-44 Years	14,701	14.4%	15,446	13.3%
45-54 Years	19,449	11.3%	20,543	10.4%
55-64 Years	13,668	7.5%	14,405	6.8%
Drug Screen in the Following 183 Days				
00-11 Years	55	4.0%	55	3.7%
12-17 Years	283	4.3%	292	4.1%
18-24 Years	3,890	17.4%	4,228	17.3%
25-34 Years	15,730	25.9%	17,191	25.4%
35-44 Years	24,370	23.9%	26,713	23.1%
45-54 Years	33,317	19.4%	36,654	18.6%
55-64 Years	24,630	13.5%	26,999	12.8%
<i>Minimum Days Supplied = 84 Days</i>				
All				
00-11 Years	80	N/A	80	N/A
12-17 Years	272	N/A	276	N/A
18-24 Years	3,359	N/A	3,468	N/A

Table 2: Percentage of New Extended-Release and Long-Acting (ER/LA) Opioid Analgesics Users and Episodes with Drug Screens in the Mini-Sentinel Distributed Database (MSDD) between January 1, 2009 and December 31, 2013, by Incidence Assessment Period/Enrollment Requirement, Minimum Days Supplied, Evidence of Prior Immediate Release (IR) Opioid Use, and Age Group

	Percentage of New Users			Percentage of New Episodes with Drug Screen
	New Users	with Drug Screen	New Episodes	Screen
25-34 Years	16,636	N/A	17,334	N/A
35-44 Years	29,930	N/A	31,232	N/A
45-54 Years	48,419	N/A	50,646	N/A
55-64 Years	43,785	N/A	45,701	N/A
Drug Screen in the Prior 30 Days				
00-11 Years	1	1.3%	1	1.3%
12-17 Years	27	9.9%	27	9.8%
18-24 Years	663	19.7%	670	19.3%
25-34 Years	3,919	23.6%	3,994	23.0%
35-44 Years	6,742	22.5%	6,854	21.9%
45-54 Years	8,924	18.4%	9,092	18.0%
55-64 Years	5,934	13.6%	6,033	13.2%
Drug Screen in the Following 183 Days				
00-11 Years	8	10.0%	8	10.0%
12-17 Years	57	21.0%	57	20.7%
18-24 Years	1,369	40.8%	1,399	40.3%
25-34 Years	7,246	43.6%	7,464	43.1%
35-44 Years	12,033	40.2%	12,391	39.7%
45-54 Years	16,190	33.4%	16,689	33.0%
55-64 Years	11,251	25.7%	11,564	25.3%
Incident ER/LA Opioid Analgesics Use with an IR Opioid Prescription in the Prior 60 Days				
183-day Incidence Assessment Period/Enrollment Requirement				
<i>Minimum Days Supplied = 1 Day</i>				
All				
00-11 Years	316	N/A	344	N/A
12-17 Years	2,097	N/A	2,244	N/A
18-24 Years	10,361	N/A	11,157	N/A
25-34 Years	37,417	N/A	40,357	N/A
35-44 Years	65,980	N/A	71,891	N/A
45-54 Years	110,957	N/A	121,635	N/A
55-64 Years	117,523	N/A	128,812	N/A
Drug Screen in the Prior 30 Days				
00-11 Years	9	2.8%	9	2.6%
12-17 Years	62	3.0%	63	2.8%
18-24 Years	1,371	13.2%	1,402	12.6%
25-34 Years	6,876	18.4%	7,066	17.5%
35-44 Years	10,740	16.3%	11,063	15.4%
45-54 Years	14,177	12.8%	14,655	12.0%
55-64 Years	10,011	8.5%	10,319	8.0%

Table 2: Percentage of New Extended-Release and Long-Acting (ER/LA) Opioid Analgesics Users and Episodes with Drug Screens in the Mini-Sentinel Distributed Database (MSDD) between January 1, 2009 and December 31, 2013, by Incidence Assessment Period/Enrollment Requirement, Minimum Days Supplied, Evidence of Prior Immediate Release (IR) Opioid Use, and Age Group

	Percentage of New Users		New Episodes	Percentage of New Episodes with Drug Screen
	New Users	with Drug Screen		
Drug Screen in the Following 183 Days				
00-11 Years	20	6.3%	20	5.8%
12-17 Years	161	7.7%	164	7.3%
18-24 Years	2,501	24.1%	2,622	23.5%
25-34 Years	11,502	30.7%	12,119	30.0%
35-44 Years	17,933	27.2%	18,917	26.3%
45-54 Years	24,189	21.8%	25,568	21.0%
55-64 Years	17,806	15.2%	18,778	14.6%
Minimum Days Supplied = 84 Days				
All				
00-11 Years	44	N/A	44	N/A
12-17 Years	180	N/A	180	N/A
18-24 Years	2,144	N/A	2,178	N/A
25-34 Years	11,749	N/A	12,016	N/A
35-44 Years	21,649	N/A	22,177	N/A
45-54 Years	34,671	N/A	35,546	N/A
55-64 Years	31,674	N/A	32,388	N/A
Drug Screen in the Prior 30 Days				
00-11 Years	1	2.3%	1	2.3%
12-17 Years	21	11.7%	21	11.7%
18-24 Years	464	21.6%	465	21.3%
25-34 Years	2,850	24.3%	2,879	24.0%
35-44 Years	4,979	23.0%	5,016	22.6%
45-54 Years	6,503	18.8%	6,576	18.5%
55-64 Years	4,420	14.0%	4,462	13.8%
Drug Screen in the Following 183 Days				
00-11 Years	3	6.8%	3	6.8%
12-17 Years	43	23.9%	43	23.9%
18-24 Years	909	42.4%	917	42.1%
25-34 Years	5,278	44.9%	5,366	44.7%
35-44 Years	8,828	40.8%	8,971	40.5%
45-54 Years	11,670	33.7%	11,876	33.4%
55-64 Years	8,145	25.7%	8,273	25.5%
Incident ER/LA Opioid Analgesics Use with an IR Opioid Prescription in the Prior 60 Days				
90-day Incidence Assessment Period/Enrollment Requirement				
Minimum Days Supplied = 1 Day				
All				
00-11 Years	331	N/A	377	N/A
12-17 Years	2,224	N/A	2,507	N/A

Table 2: Percentage of New Extended-Release and Long-Acting (ER/LA) Opioid Analgesics Users and Episodes with Drug Screens in the Mini-Sentinel Distributed Database (MSDD) between January 1, 2009 and December 31, 2013, by Incidence Assessment Period/Enrollment Requirement, Minimum Days Supplied, Evidence of Prior Immediate Release (IR) Opioid Use, and Age Group

	Percentage of New Users			Percentage of New Episodes with Drug Screen
	New Users	with Drug Screen	New Episodes	Screen
18-24 Years	11,600	N/A	13,226	N/A
25-34 Years	42,996	N/A	49,252	N/A
35-44 Years	74,571	N/A	86,762	N/A
45-54 Years	123,436	N/A	145,143	N/A
55-64 Years	128,006	N/A	150,512	N/A
Drug Screen in the Prior 30 Days				
00-11 Years	9	2.7%	9	2.4%
12-17 Years	67	3.0%	70	2.8%
18-24 Years	1,602	13.8%	1,682	12.7%
25-34 Years	8,243	19.2%	8,679	17.6%
35-44 Years	12,933	17.3%	13,646	15.7%
45-54 Years	16,910	13.7%	17,957	12.4%
55-64 Years	11,839	9.2%	12,527	8.3%
Drug Screen in the Following 183 Days				
00-11 Years	23	6.9%	23	6.1%
12-17 Years	176	7.9%	185	7.4%
18-24 Years	2,878	24.8%	3,188	24.1%
25-34 Years	13,561	31.5%	14,964	30.4%
35-44 Years	21,194	28.4%	23,436	27.0%
45-54 Years	28,545	23.1%	31,677	21.8%
55-64 Years	20,876	16.3%	23,088	15.3%
Minimum Days Supplied = 84 Days				
All				
00-11 Years	49	N/A	49	N/A
12-17 Years	199	N/A	202	N/A
18-24 Years	2,558	N/A	2,652	N/A
25-34 Years	14,216	N/A	14,877	N/A
35-44 Years	25,989	N/A	27,213	N/A
45-54 Years	41,250	N/A	43,283	N/A
55-64 Years	37,012	N/A	38,696	N/A
Drug Screen in the Prior 30 Days				
00-11 Years	1	2.0%	1	2.0%
12-17 Years	22	11.1%	22	10.9%
18-24 Years	545	21.3%	552	20.8%
25-34 Years	3,479	24.5%	3,551	23.9%
35-44 Years	6,097	23.5%	6,206	22.8%
45-54 Years	7,953	19.3%	8,114	18.7%
55-64 Years	5,319	14.4%	5,413	14.0%
Drug Screen in the Following 183 Days				

Table 2: Percentage of New Extended-Release and Long-Acting (ER/LA) Opioid Analgesics Users and Episodes with Drug Screens in the Mini-Sentinel Distributed Database (MSDD) between January 1, 2009 and December 31, 2013, by Incidence Assessment Period/Enrollment Requirement, Minimum Days Supplied, Evidence of Prior Immediate Release (IR) Opioid Use, and Age Group

	Percentage of New Users		New Episodes	Percentage of New Episodes with Drug
	New Users	with Drug Screen		Screen
00-11 Years	5	10.2%	5	10.2%
12-17 Years	46	23.1%	46	22.8%
18-24 Years	1,099	43.0%	1,127	42.5%
25-34 Years	6,393	45.0%	6,604	44.4%
35-44 Years	10,760	41.4%	11,108	40.8%
45-54 Years	14,226	34.5%	14,702	34.0%
55-64 Years	9,835	26.6%	10,131	26.2%

Appendix for Table 2: Summary of Extended-Release and Long-Acting (ER/LA) Opioid Analgesics Use and Drug Screens in the Mini-Sentinel Distributed Database (MSDD) between January 1, 2009 and December 31, 2013, by Incidence Assessment Period/Enrollment Requirement, Minimum Days Supplied, Immediate Release (IR) Exclusion Requirement, Drug Screen Inclusion Requirement, and Age Group

	New Users	New Episodes	Days Dispensings	Days Supplied	Amount Supplied	Eligible Members	Member-Years	New Users/1K Eligible Members	Days Supplied/U ser	Dispensings/U ser	Days Supplied/Dispensing
183-day Incidence Assessment Period/Enrollment Requirement (No IR opioid use exclusion requirement)											
Minimum Days Supplied = 1 Day											
All											
00-11 Years	1,136	1,185	1,819	34,073	123,611	13,243,588	23,653,228.8	0.09	29.99	1.60	18.73
12-17 Years	6,166	6,432	9,366	144,188	345,494	8,633,760	13,934,701.5	0.71	23.38	1.52	15.39
18-24 Years	19,925	20,983	54,867	1,218,051	2,766,900	10,899,562	15,582,429.6	1.83	61.13	2.75	22.20
25-34 Years	52,211	55,459	223,950	5,674,061	12,733,283	15,396,703	22,356,369.4	3.39	108.68	4.29	25.34
35-44 Years	88,999	95,608	417,254	10,954,257	23,242,633	14,963,425	25,374,172.4	5.95	123.08	4.69	26.25
45-54 Years	151,670	163,925	695,979	18,529,453	39,063,978	15,344,433	28,415,531.4	9.88	122.17	4.59	26.62
55-64 Years	165,318	178,649	630,457	16,691,279	33,231,482	11,561,026	22,931,653.4	14.30	100.96	3.81	26.47
Drug Screen in the Prior 30 Days											
00-11 Years	13	13	27	733	1,286	N/A	N/A	N/A	56.38	2.08	27.15
12-17 Years	104	105	276	6,846	14,930	N/A	N/A	N/A	65.83	2.65	24.80
18-24 Years	1,841	1,873	7,894	199,529	427,913	N/A	N/A	N/A	108.38	4.29	25.28
25-34 Years	7,791	7,989	43,856	1,168,129	2,521,911	N/A	N/A	N/A	149.93	5.63	26.64
35-44 Years	12,038	12,368	78,486	2,135,618	4,352,414	N/A	N/A	N/A	177.41	6.52	27.21
45-54 Years	16,036	16,529	110,166	3,046,370	6,283,096	N/A	N/A	N/A	189.97	6.87	27.65
55-64 Years	11,362	11,688	72,282	2,014,455	4,073,312	N/A	N/A	N/A	177.30	6.36	27.87
Drug Screen in the Following 183 Days											
00-11 Years	50	50	112	2,575	6,415	N/A	N/A	N/A	51.50	2.24	22.99
12-17 Years	254	257	765	17,838	41,861	N/A	N/A	N/A	70.23	3.01	23.32
18-24 Years	3,346	3,481	16,866	423,702	941,250	N/A	N/A	N/A	126.63	5.04	25.12
25-34 Years	13,116	13,748	82,955	2,211,001	4,844,648	N/A	N/A	N/A	168.57	6.32	26.65
35-44 Years	20,249	21,265	143,493	3,914,843	8,295,025	N/A	N/A	N/A	193.34	7.09	27.28
45-54 Years	27,648	29,090	201,741	5,573,808	11,862,892	N/A	N/A	N/A	201.60	7.30	27.63
55-64 Years	20,464	21,488	135,964	3,799,021	7,794,599	N/A	N/A	N/A	185.64	6.64	27.94
Minimum Days Supplied = 84 Days											
All											
00-11 Years	65	65	399	11,278	61,834	12,453,964	21,897,180.8	0.01	173.51	6.14	28.27
12-17 Years	240	240	2,097	55,907	151,913	8,156,421	12,987,184.4	0.03	232.95	8.74	26.66
18-24 Years	2,797	2,836	30,986	833,859	1,985,268	10,086,769	14,157,003.2	0.28	298.13	11.08	26.91
25-34 Years	13,534	13,812	166,233	4,560,847	10,582,918	14,153,632	20,206,346.8	0.96	336.99	12.28	27.44
35-44 Years	24,421	24,975	320,295	8,989,728	19,663,427	14,039,232	23,480,003.1	1.74	368.11	13.12	28.07
45-54 Years	39,712	40,638	527,390	15,017,227	32,818,500	14,554,047	26,570,440.9	2.73	378.15	13.28	28.47
55-64 Years	36,467	37,217	437,010	12,613,284	26,242,913	11,019,779	21,498,488.1	3.31	345.88	11.98	28.86
Drug Screen in the Prior 30 Days											
00-11 Years	1	1	11	426	942	N/A	N/A	N/A	426.00	11.00	38.73
12-17 Years	25	25	166	4,639	11,388	N/A	N/A	N/A	185.56	6.64	27.95
18-24 Years	567	568	5,884	157,689	349,389	N/A	N/A	N/A	278.11	10.38	26.80
25-34 Years	3,157	3,187	36,464	996,971	2,213,940	N/A	N/A	N/A	315.80	11.55	27.34
35-44 Years	5,428	5,466	67,959	1,886,602	3,915,850	N/A	N/A	N/A	347.57	12.52	27.76
45-54 Years	7,183	7,258	96,454	2,715,267	5,712,580	N/A	N/A	N/A	378.01	13.43	28.15
55-64 Years	4,849	4,892	62,394	1,770,816	3,662,094	N/A	N/A	N/A	365.19	12.87	28.38
Drug Screen in the Following 183 Days											
00-11 Years	5	5	44	1,297	2,688	N/A	N/A	N/A	259.40	8.80	29.48
12-17 Years	52	52	472	12,523	30,962	N/A	N/A	N/A	240.83	9.08	26.53

18-24 Years	1,133	1,142	13,031	345,406	785,565	N/A	N/A	N/A	304.86	11.50	26.51
25-34 Years	5,887	5,977	70,720	1,929,529	4,329,331	N/A	N/A	N/A	327.76	12.01	27.28
35-44 Years	9,734	9,880	126,133	3,502,602	7,554,035	N/A	N/A	N/A	359.83	12.96	27.77
45-54 Years	13,024	13,236	178,141	5,007,283	10,858,731	N/A	N/A	N/A	384.47	13.68	28.11
55-64 Years	9,067	9,198	118,154	3,366,970	7,047,298	N/A	N/A	N/A	371.34	13.03	28.50

90-day Incidence Assessment Period/Enrollment Requirement (No IR opioid use exclusion requirement)

Minimum Days Supplied = 1 Day

All

00-11 Years	1,380	1,471	2,277	42,239	144,182	14,544,728	25,993,704.1	0.09	30.61	1.65	18.55
12-17 Years	6,604	7,099	10,513	164,235	392,567	9,218,630	14,903,088.0	0.72	24.87	1.59	15.62
18-24 Years	22,389	24,489	65,493	1,465,537	3,363,242	12,220,087	17,228,516.2	1.83	65.46	2.93	22.38
25-34 Years	60,676	67,752	276,877	7,040,444	15,841,277	17,150,102	24,891,372.4	3.54	116.03	4.56	25.43
35-44 Years	101,923	115,849	513,228	13,533,990	29,209,805	16,168,689	27,445,003.9	6.30	132.79	5.04	26.37
45-54 Years	171,508	197,231	853,375	22,865,402	49,166,662	16,303,740	30,337,538.1	10.52	133.32	4.98	26.79
55-64 Years	183,104	210,577	756,175	20,230,306	41,209,868	12,077,112	24,186,320.4	15.16	110.49	4.13	26.75

Drug Screen in the Prior 30 Days

00-11 Years	13	13	27	733	1,286	N/A	N/A	N/A	56.38	2.08	27.15
12-17 Years	111	114	303	7,508	16,473	N/A	N/A	N/A	67.64	2.73	24.78
18-24 Years	2,151	2,238	9,285	232,801	501,300	N/A	N/A	N/A	108.23	4.32	25.07
25-34 Years	9,477	9,934	54,891	1,460,704	3,164,041	N/A	N/A	N/A	154.13	5.79	26.61
35-44 Years	14,701	15,446	98,068	2,670,352	5,569,466	N/A	N/A	N/A	181.64	6.67	27.23
45-54 Years	19,449	20,543	137,242	3,793,134	7,903,316	N/A	N/A	N/A	195.03	7.06	27.64
55-64 Years	13,668	14,405	89,067	2,488,079	5,138,642	N/A	N/A	N/A	182.04	6.52	27.93

Drug Screen in the Following 183 Days

00-11 Years	55	55	158	3,840	8,003	N/A	N/A	N/A	69.82	2.87	24.30
12-17 Years	283	292	890	20,930	48,507	N/A	N/A	N/A	73.96	3.14	23.52
18-24 Years	3,890	4,228	20,347	509,554	1,146,020	N/A	N/A	N/A	130.99	5.23	25.04
25-34 Years	15,730	17,191	103,027	2,739,822	6,026,996	N/A	N/A	N/A	174.18	6.55	26.59
35-44 Years	24,370	26,713	178,636	4,872,496	10,478,709	N/A	N/A	N/A	199.94	7.33	27.28
45-54 Years	33,317	36,654	252,401	6,974,258	15,067,754	N/A	N/A	N/A	209.33	7.58	27.63
55-64 Years	24,630	26,999	169,656	4,750,084	9,975,601	N/A	N/A	N/A	192.86	6.89	28.00

Minimum Days Supplied = 84 Days

All

00-11 Years	80	80	520	14,489	72,257	13,566,759	24,029,465.4	0.01	181.11	6.50	27.86
12-17 Years	272	276	2,444	65,500	171,848	8,667,521	13,876,982.2	0.03	240.81	8.99	26.80
18-24 Years	3,359	3,468	37,613	1,008,962	2,431,764	11,189,177	15,626,572.4	0.30	300.38	11.20	26.82
25-34 Years	16,636	17,334	206,590	5,665,968	13,141,744	15,655,694	22,465,948.5	1.06	340.58	12.42	27.43
35-44 Years	29,930	31,232	396,570	11,127,188	24,733,244	15,077,178	25,364,414.1	1.99	371.77	13.25	28.06
45-54 Years	48,419	50,646	652,996	18,605,556	41,388,723	15,393,166	28,346,820.5	3.15	384.26	13.49	28.49
55-64 Years	43,785	45,701	531,224	15,391,781	32,676,837	11,482,941	22,671,858.7	3.81	351.53	12.13	28.97

Drug Screen in the Prior 30 Days

00-11 Years	1	1	11	426	942	N/A	N/A	N/A	426.00	11.00	38.73
12-17 Years	27	27	180	5,046	12,282	N/A	N/A	N/A	186.89	6.67	28.03
18-24 Years	663	670	6,833	182,093	404,969	N/A	N/A	N/A	274.65	10.31	26.65
25-34 Years	3,919	3,994	45,655	1,248,466	2,778,901	N/A	N/A	N/A	318.57	11.65	27.35
35-44 Years	6,742	6,854	84,908	2,359,868	5,019,274	N/A	N/A	N/A	350.02	12.59	27.79
45-54 Years	8,924	9,092	120,279	3,382,367	7,179,015	N/A	N/A	N/A	379.02	13.48	28.12
55-64 Years	5,934	6,033	76,903	2,186,672	4,620,860	N/A	N/A	N/A	368.50	12.96	28.43

Drug Screen in the Following 183 Days

00-11 Years	8	8	86	2,510	4,201	N/A	N/A	N/A	313.75	10.75	29.19
12-17 Years	57	57	546	14,728	35,290	N/A	N/A	N/A	258.39	9.58	26.97
18-24 Years	1,369	1,399	15,681	414,268	957,476	N/A	N/A	N/A	302.61	11.45	26.42
25-34 Years	7,246	7,464	87,622	2,385,808	5,365,707	N/A	N/A	N/A	329.26	12.09	27.23
35-44 Years	12,033	12,391	156,717	4,351,765	9,523,122	N/A	N/A	N/A	361.65	13.02	27.77
45-54 Years	16,190	16,689	222,758	6,257,468	13,762,171	N/A	N/A	N/A	386.50	13.76	28.09
55-64 Years	11,251	11,564	147,442	4,205,081	9,002,367	N/A	N/A	N/A	373.75	13.10	28.52

183-day Incidence Assessment Period/Enrollment Requirement (IR opioid use exclusion requirement)

Minimum Days Supplied = 1 Day

All

00-11 Years	820	841	1,097	17,942	52,820	13,240,788	23,504,722.7	0.06	21.88	1.34	16.36
12-17 Years	4,069	4,188	5,111	64,482	157,730	8,625,427	13,676,548.0	0.47	15.85	1.26	12.62
18-24 Years	9,564	9,826	17,568	316,614	786,730	10,865,595	15,015,994.8	0.88	33.10	1.84	18.02
25-34 Years	14,794	15,102	36,538	794,835	2,174,968	15,277,982	21,204,915.3	0.97	53.73	2.47	21.75
35-44 Years	23,019	23,717	59,420	1,371,971	3,395,432	14,775,692	23,839,890.9	1.56	59.60	2.58	23.09
45-54 Years	40,713	42,290	108,942	2,610,467	6,350,733	15,060,518	26,301,960.4	2.70	64.12	2.68	23.96
55-64 Years	47,795	49,837	108,642	2,542,302	5,566,928	11,303,534	20,929,471.0	4.23	53.19	2.27	23.40

Drug Screen in the Prior 30 Days

00-11 Years	4	4	5	69	147	N/A	N/A	N/A	17.25	1.25	13.80
12-17 Years	42	42	80	1,803	6,168	N/A	N/A	N/A	42.93	1.90	22.54
18-24 Years	470	471	1,485	33,564	94,582	N/A	N/A	N/A	71.41	3.16	22.60
25-34 Years	915	923	4,603	111,893	323,714	N/A	N/A	N/A	122.29	5.03	24.31
35-44 Years	1,298	1,305	6,105	163,090	394,453	N/A	N/A	N/A	125.65	4.70	26.71
45-54 Years	1,859	1,874	11,042	298,200	760,250	N/A	N/A	N/A	160.41	5.94	27.01
55-64 Years	1,351	1,369	6,920	192,072	467,200	N/A	N/A	N/A	142.17	5.12	27.76

Drug Screen in the Following 183 Days

00-11 Years	30	30	63	1,304	3,522	N/A	N/A	N/A	43.47	2.10	20.70
12-17 Years	93	93	198	4,189	12,023	N/A	N/A	N/A	45.04	2.13	21.16
18-24 Years	845	859	3,370	75,954	201,597	N/A	N/A	N/A	89.89	3.99	22.54
25-34 Years	1,614	1,629	8,779	220,770	636,043	N/A	N/A	N/A	136.78	5.44	25.15
35-44 Years	2,316	2,348	13,784	367,503	976,265	N/A	N/A	N/A	158.68	5.95	26.66
45-54 Years	3,459	3,522	21,508	587,741	1,540,615	N/A	N/A	N/A	169.92	6.22	27.33
55-64 Years	2,658	2,710	14,828	410,509	1,066,034	N/A	N/A	N/A	154.44	5.58	27.68

Minimum Days Supplied = 84 Days

All

00-11 Years	21	21	129	3,668	10,624	12,450,682	21,759,367.8	0.00	174.67	6.14	28.43
12-17 Years	60	60	520	14,274	44,446	8,147,729	12,746,038.4	0.01	237.90	8.67	27.45
18-24 Years	653	658	6,233	163,058	443,919	10,051,655	13,643,135.2	0.06	249.71	9.55	26.16
25-34 Years	1,785	1,796	19,767	531,887	1,601,964	14,038,982	19,173,236.2	0.13	297.98	11.07	26.91
35-44 Years	2,772	2,798	33,536	939,805	2,514,787	13,857,874	22,072,723.0	0.20	339.03	12.10	28.02
45-54 Years	5,041	5,092	63,198	1,801,924	4,775,526	14,277,842	24,605,597.3	0.35	357.45	12.54	28.51
55-64 Years	4,793	4,829	53,378	1,553,794	3,737,081	10,767,494	19,628,940.5	0.45	324.18	11.14	29.11

Drug Screen in the Prior 30 Days

00-11 Years	0	0	0	0	0	N/A	N/A	N/A	---	---	---
12-17 Years	4	4	32	897	4,759	N/A	N/A	N/A	224.25	8.00	28.03
18-24 Years	103	103	947	24,400	71,363	N/A	N/A	N/A	236.89	9.19	25.77
25-34 Years	307	308	3,662	92,157	282,156	N/A	N/A	N/A	300.19	11.93	25.17
35-44 Years	449	450	4,859	135,419	336,864	N/A	N/A	N/A	301.60	10.82	27.87
45-54 Years	680	682	9,353	258,716	685,151	N/A	N/A	N/A	380.46	13.75	27.66
55-64 Years	429	430	5,642	161,400	412,405	N/A	N/A	N/A	376.22	13.15	28.61

Drug Screen in the Following 183 Days

00-11 Years	2	2	19	471	508	N/A	N/A	N/A	235.50	9.50	24.79
12-17 Years	9	9	91	2,567	8,644	N/A	N/A	N/A	285.22	10.11	28.21
18-24 Years	224	225	2,285	57,509	151,824	N/A	N/A	N/A	256.74	10.20	25.17
25-34 Years	609	611	7,183	188,203	564,693	N/A	N/A	N/A	309.04	11.79	26.20
35-44 Years	906	909	11,639	320,000	872,824	N/A	N/A	N/A	353.20	12.85	27.49
45-54 Years	1,354	1,360	18,422	516,364	1,394,885	N/A	N/A	N/A	381.36	13.61	28.03
55-64 Years	922	925	12,352	352,468	955,420	N/A	N/A	N/A	382.29	13.40	28.54

90-day Incidence Assessment Period/Enrollment Requirement (IR opioid use exclusion requirement)

Minimum Days Supplied = 1 Day

All

00-11 Years	1,049	1,094	1,463	23,967	70,768	14,541,772	25,834,145.2	0.07	22.85	1.39	16.38
12-17 Years	4,380	4,592	5,691	73,321	178,074	9,210,267	14,628,838.1	0.48	16.74	1.30	12.88
18-24 Years	10,789	11,263	20,836	385,672	1,000,439	12,181,707	16,603,954.3	0.89	35.75	1.93	18.51
25-34 Years	17,680	18,500	46,931	1,048,515	2,881,172	17,017,553	23,608,549.8	1.04	59.31	2.65	22.34

35-44 Years	27,352	29,087	79,841	1,914,943	4,970,662	15,968,177	25,774,121.2	1.71	70.01	2.92	23.98
45-54 Years	48,072	52,088	146,090	3,632,014	9,198,512	16,009,761	28,067,114.3	3.00	75.55	3.04	24.86
55-64 Years	55,098	60,065	141,040	3,463,451	8,032,644	11,817,178	22,060,313.3	4.66	62.86	2.56	24.56

Drug Screen in the Prior 30 Days

00-11 Years	4	4	5	69	147	N/A	N/A	N/A	17.25	1.25	13.80
12-17 Years	44	44	87	2,010	6,702	N/A	N/A	N/A	45.68	1.98	23.10
18-24 Years	549	556	1,719	38,103	108,688	N/A	N/A	N/A	69.40	3.13	22.17
25-34 Years	1,234	1,255	6,424	158,057	462,431	N/A	N/A	N/A	128.09	5.21	24.60
35-44 Years	1,768	1,800	9,006	242,727	635,066	N/A	N/A	N/A	137.29	5.09	26.95
45-54 Years	2,539	2,586	15,488	422,207	1,108,775	N/A	N/A	N/A	166.29	6.10	27.26
55-64 Years	1,829	1,878	9,842	277,426	730,040	N/A	N/A	N/A	151.68	5.38	28.19

Drug Screen in the Following 183 Days

00-11 Years	32	32	69	1,437	3,865	N/A	N/A	N/A	44.91	2.16	20.83
12-17 Years	107	107	250	5,563	14,987	N/A	N/A	N/A	51.99	2.34	22.25
18-24 Years	1,012	1,040	4,133	94,200	267,896	N/A	N/A	N/A	93.08	4.08	22.79
25-34 Years	2,169	2,227	11,909	300,388	877,829	N/A	N/A	N/A	138.49	5.49	25.22
35-44 Years	3,176	3,277	19,204	513,373	1,430,357	N/A	N/A	N/A	161.64	6.05	26.73
45-54 Years	4,772	4,977	31,209	856,062	2,270,038	N/A	N/A	N/A	179.39	6.54	27.43
55-64 Years	3,754	3,911	22,321	624,831	1,671,144	N/A	N/A	N/A	166.44	5.95	27.99

Minimum Days Supplied = 84 Days

All

00-11 Years	31	31	195	5,319	19,423	13,563,736	23,881,563.4	0.00	171.58	6.29	27.28
12-17 Years	73	74	655	18,086	51,364	8,659,136	13,621,005.1	0.01	247.75	8.97	27.61
18-24 Years	801	816	7,815	205,183	593,921	11,152,518	15,061,472.0	0.07	256.16	9.76	26.26
25-34 Years	2,420	2,457	26,565	718,724	2,135,074	15,534,135	21,318,476.4	0.16	296.99	10.98	27.06
35-44 Years	3,941	4,019	48,583	1,365,421	3,807,541	14,888,787	23,835,094.5	0.26	346.47	12.33	28.10
45-54 Years	7,169	7,363	90,819	2,603,472	7,086,153	15,112,120	26,238,188.6	0.47	363.16	12.67	28.67
55-64 Years	6,773	7,005	75,779	2,236,626	5,626,684	11,230,357	20,686,746.8	0.60	330.23	11.19	29.52

Drug Screen in the Prior 30 Days

00-11 Years	0	0	0	0	0	N/A	N/A	N/A	---	---	---
12-17 Years	5	5	38	1,074	5,113	N/A	N/A	N/A	214.80	7.60	28.26
18-24 Years	118	118	1,073	26,820	80,614	N/A	N/A	N/A	227.29	9.09	25.00
25-34 Years	440	443	5,179	132,045	406,014	N/A	N/A	N/A	300.10	11.77	25.50
35-44 Years	645	648	7,313	204,553	554,250	N/A	N/A	N/A	317.14	11.34	27.97
45-54 Years	971	978	13,183	367,906	999,497	N/A	N/A	N/A	378.89	13.58	27.91
55-64 Years	615	620	8,121	235,336	650,369	N/A	N/A	N/A	382.66	13.20	28.98

Drug Screen in the Following 183 Days

00-11 Years	3	3	24	574	821	N/A	N/A	N/A	191.33	8.00	23.92
12-17 Years	11	11	128	3,704	10,678	N/A	N/A	N/A	336.73	11.64	28.94
18-24 Years	270	272	2,820	71,281	208,423	N/A	N/A	N/A	264.00	10.44	25.28
25-34 Years	853	860	9,712	255,740	770,756	N/A	N/A	N/A	299.81	11.39	26.33
35-44 Years	1,273	1,283	16,247	446,153	1,278,721	N/A	N/A	N/A	350.47	12.76	27.46
45-54 Years	1,964	1,987	26,943	754,764	2,048,704	N/A	N/A	N/A	384.30	13.72	28.01
55-64 Years	1,416	1,433	18,913	542,304	1,499,416	N/A	N/A	N/A	382.98	13.36	28.67

Table 3: Percentage of New Extended-Release and Long-Acting (ER/LA) Opioid Analgesics Users and Episodes with Drug Screens in the Mini-Sentinel Distributed Database (MSDD) between January 1, 2009 and December 31, 2013, by Incidence Assessment Period/Enrollment Requirement, Minimum Days Supplied, Evidence of Prior Immediate Release (IR) Opioid Use, and Sex

	New Users	Percentage of New Users with Drug Screen	New Episodes	Percentage of New Episodes with Drug Screen
All Incident ER/LA Opioid Analgesics Use				
183-day Incidence Assessment Period/Enrollment Requirement				
<i>Minimum Days Supplied = 1 Day</i>				
All				
Female	249,102	N/A	272,321	N/A
Male	230,690	N/A	249,887	N/A
Unknown	28	N/A	33	N/A
Drug Screen in the Prior 30 Days				
Female	26,529	10.6%	27,436	10.1%
Male	22,420	9.7%	23,123	9.3%
Unknown	5	17.9%	6	18.2%
Drug Screen in the Following 183 Days				
Female	46,121	18.5%	48,957	18.0%
Male	38,357	16.6%	40,414	16.2%
Unknown	7	25.0%	8	24.2%
<i>Minimum Days Supplied = 84 Days</i>				
All				
Female	61,414	N/A	63,117	N/A
Male	55,267	N/A	56,657	N/A
Unknown	9	N/A	9	N/A
Drug Screen in the Prior 30 Days				
Female	11,345	18.5%	11,456	18.2%
Male	9,828	17.8%	9,938	17.5%
Unknown	3	33.3%	3	33.3%
Drug Screen in the Following 183 Days				
Female	20,983	34.2%	21,364	33.8%
Male	17,805	32.2%	18,121	32.0%
Unknown	5	55.6%	5	55.6%
90-day Incidence Assessment Period/Enrollment Requirement				
<i>Minimum Days Supplied = 1 Day</i>				
All				
Female	279,893	N/A	326,659	N/A
Male	259,207	N/A	297,771	N/A
Unknown	29	N/A	38	N/A
Drug Screen in the Prior 30 Days				
Female	31,946	11.4%	33,937	10.4%
Male	27,209	10.5%	28,749	9.7%
Unknown	6	20.7%	7	18.4%
Drug Screen in the Following 183 Days				
Female	55,118	19.7%	61,421	18.8%
Male	46,028	17.8%	50,699	17.0%
Unknown	8	27.6%	12	31.6%
<i>Minimum Days Supplied = 84 Days</i>				

Table 3: Percentage of New Extended-Release and Long-Acting (ER/LA) Opioid Analgesics Users and Episodes with Drug Screens in the Mini-Sentinel Distributed Database (MSDD) between January 1, 2009 and December 31, 2013, by Incidence Assessment Period/Enrollment Requirement, Minimum Days Supplied, Evidence of Prior Immediate Release (IR) Opioid Use, and Sex

	New Users	Percentage of New Users with Drug Screen	New Episodes	Percentage of New Episodes with Drug Screen
All				
Female	74,447	N/A	78,395	N/A
Male	66,947	N/A	70,332	N/A
Unknown	10	N/A	10	N/A
Drug Screen in the Prior 30 Days				
Female	13,987	18.8%	14,271	18.2%
Male	12,139	18.1%	12,397	17.6%
Unknown	3	30.0%	3	30.0%
Drug Screen in the Following 183 Days				
Female	25,854	34.7%	26,763	34.1%
Male	22,061	33.0%	22,804	32.4%
Unknown	5	50.0%	5	50.0%
Incident ER/LA Opioid Analgesics Use with an IR Opioid Prescription in the Prior 60 Days				
183-day Incidence Assessment Period/Enrollment Requirement				
Minimum Days Supplied = 1 Day				
All				
Female	180,732	N/A	201,130	N/A
Male	158,979	N/A	175,285	N/A
Unknown	20	N/A	25	N/A
Drug Screen in the Prior 30 Days				
Female	23,681	13.1%	24,571	12.2%
Male	19,335	12.2%	20,000	11.4%
Unknown	5	25.0%	6	24.0%
Drug Screen in the Following 183 Days				
Female	40,848	22.6%	43,593	21.7%
Male	32,629	20.5%	34,587	19.7%
Unknown	7	35.0%	8	32.0%
Minimum Days Supplied = 84 Days				
All				
Female	54,348	N/A	55,970	N/A
Male	47,236	N/A	48,551	N/A
Unknown	8	N/A	8	N/A
Drug Screen in the Prior 30 Days				
Female	10,430	19.2%	10,539	18.8%
Male	8,771	18.6%	8,878	18.3%
Unknown	3	37.5%	3	37.5%
Drug Screen in the Following 183 Days				
Female	19,121	35.2%	19,494	34.8%
Male	15,642	33.1%	15,950	32.9%
Unknown	5	62.5%	5	62.5%
90-day Incidence Assessment Period/Enrollment Requirement				
Minimum Days Supplied = 1 Day				
All				

Table 3: Percentage of New Extended-Release and Long-Acting (ER/LA) Opioid Analgesics Users and Episodes with Drug Screens in the Mini-Sentinel Distributed Database (MSDD) between January 1, 2009 and December 31, 2013, by Incidence Assessment Period/Enrollment Requirement, Minimum Days Supplied, Evidence of Prior Immediate Release (IR) Opioid Use, and Sex

	New Users	Percentage of New Users with Drug Screen	New Episodes	Percentage of New Episodes with Drug Screen
Female	199,897	N/A	239,830	N/A
Male	175,985	N/A	207,919	N/A
Unknown	21	N/A	30	N/A
Drug Screen in the Prior 30 Days				
Female	28,100	14.1%	30,010	12.5%
Male	23,104	13.1%	24,553	11.8%
Unknown	6	28.6%	7	23.3%
Drug Screen in the Following 183 Days				
Female	47,755	23.9%	53,761	22.4%
Male	38,418	21.8%	42,788	20.6%
Unknown	8	38.1%	12	40.0%
<hr/>				
Minimum Days Supplied = 84 Days				
All				
Female	64,435	N/A	68,034	N/A
Male	55,837	N/A	58,929	N/A
Unknown	9	N/A	9	N/A
Drug Screen in the Prior 30 Days				
Female	12,692	19.7%	12,965	19.1%
Male	10,641	19.1%	10,891	18.5%
Unknown	3	33.3%	3	33.3%
Drug Screen in the Following 183 Days				
Female	23,115	35.9%	23,992	35.3%
Male	19,016	34.1%	19,726	33.5%
Unknown	5	55.6%	5	55.6%

Appendix for Table 3: Summary of Extended-Release and Long-Acting (ER/LA) Opioid Analgesics Use and Drug Screens in the Mini-Sentinel Distributed Database (MSDD) between January 1, 2009 and December 31, 2013, by Incidence Assessment Period/Enrollment Requirement, Minimum Days Supplied, Immediate Release (IR) Exclusion Requirement, Drug Screen Inclusion Requirement, and Sex

	New Users	New Episodes	Days Dispensings	Days Supplied	Amount Supplied	Eligible Members	Member-Years	New Eligible Members	Days Supplied/User	Dispensings/User	Days Supplied/Dispensing
183-day Incidence Assessment Period/Enrollment Requirement (No IR opioid use exclusion requirement)											
Minimum Days Supplied = 1 Day											
All											
Female	249,102	272,321	1,057,107	#####	54,918,944	37,699,781	77,376,916.9	6.61	111.80	4.24	26.35
Male	230,690	249,887	976,466	#####	56,583,134	37,012,034	74,865,524.8	6.23	110.07	4.23	26.00
Unknown	28	33	119	2,998	5,305	3,166	5,644.9	8.84	107.07	4.25	25.19
Drug Screen in the Prior 30 Days											
Female	26,529	27,436	165,426	4,548,769	8,753,763	N/A	N/A	N/A	171.46	6.24	27.50
Male	22,420	23,123	147,528	4,022,052	8,919,956	N/A	N/A	N/A	179.40	6.58	27.26
Unknown	5	6	33	859	1,144	N/A	N/A	N/A	171.80	6.60	26.03
Drug Screen in the Following 183 Days											
Female	46,121	48,957	309,203	8,514,293	16,919,758	N/A	N/A	N/A	184.61	6.70	27.54
Male	38,357	40,414	272,645	7,427,252	16,865,111	N/A	N/A	N/A	193.63	7.11	27.24
Unknown	7	8	48	1,243	1,820	N/A	N/A	N/A	177.57	6.86	25.90
Minimum Days Supplied = 84 Days											
All											
Female	61,414	63,117	772,770	#####	44,810,356	35,538,362	71,583,038.0	1.73	357.79	12.58	28.43
Male	55,267	56,657	711,550	#####	46,691,902	34,799,609	69,208,490.4	1.59	363.80	12.87	28.26
Unknown	9	9	90	2,493	4,514	2,896	5,118.9	3.11	277.00	10.00	27.70
Drug Screen in the Prior 30 Days											
Female	11,345	11,456	141,644	3,975,264	7,808,364	N/A	N/A	N/A	350.40	12.49	28.07
Male	9,828	9,938	127,659	3,556,393	8,056,763	N/A	N/A	N/A	361.86	12.99	27.86
Unknown	3	3	29	753	1,056	N/A	N/A	N/A	251.00	9.67	25.97
Drug Screen in the Following 183 Days											
Female	20,983	21,364	267,993	7,529,740	15,247,717	N/A	N/A	N/A	358.85	12.77	28.10
Male	17,805	18,121	238,657	6,634,677	15,359,173	N/A	N/A	N/A	372.63	13.40	27.80
Unknown	5	5	45	1,193	1,720	N/A	N/A	N/A	238.60	9.00	26.51
90-day Incidence Assessment Period/Enrollment Requirement (No IR opioid use exclusion requirement)											
Minimum Days Supplied = 1 Day											
All											
Female	279,893	326,659	1,288,647	#####	68,866,806	40,829,661	83,762,867.7	6.86	122.22	4.60	26.55
Male	259,207	297,771	1,189,158	#####	70,454,673	40,227,598	81,216,484.0	6.44	120.10	4.59	26.18
Unknown	29	38	133	3,383	6,124	3,649	6,191.5	7.95	116.66	4.59	25.44
Drug Screen in the Prior 30 Days											
Female	31,946	33,937	204,606	5,629,947	10,981,475	N/A	N/A	N/A	176.23	6.40	27.52
Male	27,209	28,749	184,242	5,022,445	11,311,785	N/A	N/A	N/A	184.59	6.77	27.26
Unknown	6	7	35	919	1,264	N/A	N/A	N/A	153.17	5.83	26.26
Drug Screen in the Following 183 Days											
Female	55,118	61,421	384,590	#####	21,380,141	N/A	N/A	N/A	192.17	6.98	27.54
Male	46,028	50,699	340,469	9,277,686	21,369,156	N/A	N/A	N/A	201.57	7.40	27.25
Unknown	8	12	56	1,455	2,293	N/A	N/A	N/A	181.88	7.00	25.98
Minimum Days Supplied = 84 Days											
All											
Female	74,447	78,395	951,124	#####	56,295,710	38,214,800	77,400,774.3	1.95	363.96	12.78	28.49
Male	66,947	70,332	876,737	#####	58,315,846	37,516,593	74,975,699.6	1.78	370.16	13.10	28.27
Unknown	10	10	96	2,666	4,860	3,236	5,587.8	3.09	266.60	9.60	27.77
Drug Screen in the Prior 30 Days											

Female	13,987	14,271	175,219	4,922,379	9,794,479	N/A	N/A	N/A	351.93	12.53	28.09
Male	12,139	12,397	159,521	4,441,806	10,220,709	N/A	N/A	N/A	365.91	13.14	27.84
Unknown	3	3	29	753	1,056	N/A	N/A	N/A	251.00	9.67	25.97
Drug Screen in the Following 183 Days											
Female	25,854	26,763	332,935	9,352,254	19,218,533	N/A	N/A	N/A	361.73	12.88	28.09
Male	22,061	22,804	297,872	8,278,181	19,430,080	N/A	N/A	N/A	375.24	13.50	27.79
Unknown	5	5	45	1,193	1,720	N/A	N/A	N/A	238.60	9.00	26.51

183-day Incidence Assessment Period/Enrollment Requirement (IR opioid use exclusion requirement)
Minimum Days Supplied = 1 Day

All											
Female	68,370	71,191	157,857	3,634,054	7,662,208	37,316,324	72,867,309.1	1.83	53.15	2.31	23.02
Male	71,711	74,602	179,448	4,084,302	10,822,686	36,717,959	71,600,854.4	1.95	56.96	2.50	22.76
Unknown	8	8	13	257	448	3,141	5,339.4	2.55	32.13	1.63	19.77
Drug Screen in the Prior 30 Days											
Female	2,848	2,865	13,326	358,983	791,107	N/A	N/A	N/A	126.05	4.68	26.94
Male	3,085	3,123	16,914	441,708	1,255,407	N/A	N/A	N/A	143.18	5.48	26.11
Unknown	0	0	0	0	0	N/A	N/A	N/A	---	---	---
Drug Screen in the Following 183 Days											
Female	5,273	5,364	27,684	750,208	1,740,785	N/A	N/A	N/A	142.27	5.25	27.10
Male	5,728	5,827	34,846	917,762	2,695,314	N/A	N/A	N/A	160.22	6.08	26.34
Unknown	0	0	0	0	0	N/A	N/A	N/A	---	---	---

Minimum Days Supplied = 84 Days

All											
Female	7,066	7,147	79,615	2,285,107	5,162,659	35,156,538	67,426,966.8	0.20	323.39	11.27	28.70
Male	8,031	8,106	97,141	2,723,157	7,965,492	34,509,611	66,197,235.1	0.23	339.08	12.10	28.03
Unknown	1	1	5	146	196	2,875	4,836.5	0.35	146.00	5.00	29.20
Drug Screen in the Prior 30 Days											
Female	915	917	10,595	296,221	680,282	N/A	N/A	N/A	323.74	11.58	27.96
Male	1,057	1,060	13,900	376,768	1,112,417	N/A	N/A	N/A	356.45	13.15	27.11
Unknown	0	0	0	0	0	N/A	N/A	N/A	---	---	---
Drug Screen in the Following 183 Days											
Female	1,862	1,870	22,689	637,304	1,528,034	N/A	N/A	N/A	342.27	12.19	28.09
Male	2,163	2,171	29,302	800,278	2,420,764	N/A	N/A	N/A	369.99	13.55	27.31
Unknown	0	0	0	0	0	N/A	N/A	N/A	---	---	---

90-day Incidence Assessment Period/Enrollment Requirement (IR opioid use exclusion requirement)
Minimum Days Supplied = 1 Day

All											
Female	79,996	86,829	208,101	5,011,943	11,282,121	40,432,973	78,891,349.8	1.98	62.65	2.60	24.08
Male	83,222	89,852	233,778	5,529,683	15,049,702	39,919,784	77,679,825.8	2.08	66.44	2.81	23.65
Unknown	8	8	13	257	448	3,617	5,860.6	2.21	32.13	1.63	19.77
Drug Screen in the Prior 30 Days											
Female	3,846	3,927	18,593	505,531	1,177,529	N/A	N/A	N/A	131.44	4.83	27.19
Male	4,105	4,196	23,978	635,068	1,874,321	N/A	N/A	N/A	154.71	5.84	26.49
Unknown	0	0	0	0	0	N/A	N/A	N/A	---	---	---
Drug Screen in the Following 183 Days											
Female	7,363	7,660	40,356	1,103,163	2,692,416	N/A	N/A	N/A	149.83	5.48	27.34
Male	7,610	7,911	48,739	1,292,691	3,843,699	N/A	N/A	N/A	169.87	6.40	26.52
Unknown	0	0	0	0	0	N/A	N/A	N/A	---	---	---

Minimum Days Supplied = 84 Days

All											
Female	10,012	10,361	114,270	3,310,244	7,935,126	37,830,962	72,917,473.1	0.26	330.63	11.41	28.97
Male	11,110	11,403	136,136	3,842,441	11,384,837	37,223,282	71,719,791.1	0.30	345.85	12.25	28.23
Unknown	1	1	5	146	196	3,215	5,282.6	0.31	146.00	5.00	29.20
Drug Screen in the Prior 30 Days											
Female	1,295	1,306	14,863	419,045	1,014,971	N/A	N/A	N/A	323.59	11.48	28.19
Male	1,498	1,506	20,044	548,689	1,680,885	N/A	N/A	N/A	366.28	13.38	27.37

Unknown	0	0	0	0	0	N/A	N/A	N/A	---	---	---
Drug Screen in the Following 183 Days											
Female	2,739	2,771	33,356	940,676	2,356,718	N/A	N/A	N/A	343.44	12.18	28.20
Male	3,045	3,078	41,431	1,133,844	3,460,801	N/A	N/A	N/A	372.36	13.61	27.37
Unknown	0	0	0	0	0	N/A	N/A	N/A	---	---	---

Table 4: Percentage of New Extended-Release and Long-Acting (ER/LA) Opioid Analgesics Users and Episodes with Drug Screens in the Mini-Sentinel Distributed Database (MSDD) between January 1, 2009 and December 31, 2013, by Incidence Assessment Period/Enrollment Requirement, Minimum Days Supplied, Evidence of Prior Immediate Release (IR) Opioid Use, and Year

	New Users	Percentage of New Users with Drug Screen	New Episodes	Percentage of New Episodes with Drug Screen
All Incident ER/LA Opioid Analgesics Use				
183-day Incidence Assessment Period/Enrollment Requirement				
<i>Minimum Days Supplied = 1 Day</i>				
All				
2009	115,493	N/A	116,370	N/A
2010	108,300	N/A	109,124	N/A
2011	105,085	N/A	105,865	N/A
2012	101,723	N/A	102,476	N/A
2013	87,779	N/A	88,406	N/A
Drug Screen in the Prior 30 Days				
2009	7,330	6.3%	7,342	6.3%
2010	9,090	8.4%	9,111	8.3%
2011	10,859	10.3%	10,889	10.3%
2012	12,887	12.7%	12,933	12.6%
2013	10,269	11.7%	10,290	11.6%
Drug Screen in the Following 183 Days				
2009	14,706	12.7%	14,755	12.7%
2010	16,866	15.6%	16,930	15.5%
2011	18,985	18.1%	19,078	18.0%
2012	21,141	20.8%	21,212	20.7%
2013	17,334	19.7%	17,404	19.7%
<i>Minimum Days Supplied = 84 Days</i>				
All				
2009	26,756	N/A	26,760	N/A
2010	24,982	N/A	24,994	N/A
2011	24,593	N/A	24,601	N/A
2012	23,949	N/A	23,959	N/A
2013	19,467	N/A	19,469	N/A
Drug Screen in the Prior 30 Days				
2009	3,151	11.8%	3,151	11.8%
2010	4,072	16.3%	4,072	16.3%
2011	4,640	18.9%	4,640	18.9%
2012	5,277	22.0%	5,277	22.0%
2013	4,257	21.9%	4,257	21.9%
Drug Screen in the Following 183 Days				
2009	6,600	24.7%	6,600	24.7%
2010	7,686	30.8%	7,689	30.8%
2011	8,447	34.3%	8,449	34.3%
2012	9,311	38.9%	9,314	38.9%
2013	7,438	38.2%	7,438	38.2%
All Incident ER/LA Opioid Analgesics Use				
90-day Incidence Assessment Period/Enrollment Requirement				
<i>Minimum Days Supplied = 1 Day</i>				
All				
2009	134,591	N/A	139,415	N/A
2010	125,744	N/A	130,176	N/A

Table 4: Percentage of New Extended-Release and Long-Acting (ER/LA) Opioid Analgesics Users and Episodes with Drug Screens in the Mini-Sentinel Distributed Database (MSDD) between January 1, 2009 and December 31, 2013, by Incidence Assessment Period/Enrollment Requirement, Minimum Days Supplied, Evidence of Prior Immediate Release (IR) Opioid Use, and Year

	New Users	Percentage of New Users with Drug		Percentage of New Episodes with Drug	
		Screen	New Episodes	Screen	
2011	122,115	N/A	126,455	N/A	
2012	118,207	N/A	122,345	N/A	
2013	102,700	N/A	106,077	N/A	
Drug Screen in the Prior 30 Days					
2009	9,020	6.7%	9,093	6.5%	
2010	11,087	8.8%	11,195	8.6%	
2011	13,227	10.8%	13,394	10.6%	
2012	15,750	13.3%	15,964	13.0%	
2013	12,879	12.5%	13,047	12.3%	
Drug Screen in the Following 183 Days					
2009	18,278	13.6%	18,664	13.4%	
2010	20,640	16.4%	21,057	16.2%	
2011	23,185	19.0%	23,759	18.8%	
2012	25,879	21.9%	26,485	21.6%	
2013	21,677	21.1%	22,167	20.9%	
All Incident ER/LA Opioid Analgesics Use					
90-day Incidence Assessment Period/Enrollment Requirement					
<i>Minimum Days Supplied = 84 Days</i>					
All					
2009	33,063	N/A	33,184	N/A	
2010	30,890	N/A	30,996	N/A	
2011	30,299	N/A	30,411	N/A	
2012	29,622	N/A	29,720	N/A	
2013	24,337	N/A	24,426	N/A	
Drug Screen in the Prior 30 Days					
2009	3,893	11.8%	3,898	11.7%	
2010	5,017	16.2%	5,018	16.2%	
2011	5,734	18.9%	5,747	18.9%	
2012	6,587	22.2%	6,594	22.2%	
2013	5,409	22.2%	5,414	22.2%	
Drug Screen in the Following 183 Days					
2009	8,302	25.1%	8,323	25.1%	
2010	9,536	30.9%	9,550	30.8%	
2011	10,481	34.6%	10,510	34.6%	
2012	11,625	39.2%	11,654	39.2%	
2013	9,514	39.1%	9,535	39.0%	
Incident ER/LA Opioid Analgesics Use with an IR Opioid Prescription in the Prior 60 Days					
183-day Incidence Assessment Period/Enrollment Requirement					
All					
2009	82,821	N/A	83,558	N/A	
2010	78,144	N/A	78,839	N/A	
2011	76,149	N/A	76,784	N/A	
2012	73,699	N/A	74,307	N/A	
2013	62,458	N/A	62,952	N/A	
Drug Screen in the Prior 30 Days					
2009	6,394	7.7%	6,405	7.7%	
2010	8,059	10.3%	8,079	10.2%	

Table 4: Percentage of New Extended-Release and Long-Acting (ER/LA) Opioid Analgesics Users and Episodes with Drug Screens in the Mini-Sentinel Distributed Database (MSDD) between January 1, 2009 and December 31, 2013, by Incidence Assessment Period/Enrollment Requirement, Minimum Days Supplied, Evidence of Prior Immediate Release (IR) Opioid Use, and Year

	New Users	Percentage of New Users with Drug		Percentage of New Episodes with Drug	
		Screen	New Episodes	Screen	
2011	9,599	12.6%	9,628	12.5%	
2012	11,369	15.4%	11,413	15.4%	
2013	9,032	14.5%	9,052	14.4%	
Drug Screen in the Following 183 Days					
2009	12,688	15.3%	12,731	15.2%	
2010	14,802	18.9%	14,864	18.9%	
2011	16,699	21.9%	16,786	21.9%	
2012	18,586	25.2%	18,653	25.1%	
2013	15,089	24.2%	15,154	24.1%	
Minimum Days Supplied = 84 Days					
All					
2009	22,943	N/A	22,946	N/A	
2010	21,787	N/A	21,799	N/A	
2011	21,541	N/A	21,547	N/A	
2012	21,129	N/A	21,138	N/A	
2013	17,097	N/A	17,099	N/A	
Drug Screen in the Prior 30 Days					
2009	2,842	12.4%	2,842	12.4%	
2010	3,721	17.1%	3,721	17.1%	
2011	4,217	19.6%	4,217	19.6%	
2012	4,785	22.6%	4,785	22.6%	
2013	3,855	22.5%	3,855	22.5%	
Drug Screen in the Following 183 Days					
2009	5,862	25.6%	5,862	25.5%	
2010	6,889	31.6%	6,892	31.6%	
2011	7,615	35.4%	7,617	35.4%	
2012	8,391	39.7%	8,393	39.7%	
2013	6,685	39.1%	6,685	39.1%	
Incident ER/LA Opioid Analgesics Use with an IR Opioid Prescription in the Prior 60 Days					
90-day Incidence Assessment Period/Enrollment Requirement					
Minimum Days Supplied = 1 Day					
All					
2009	95,502	N/A	99,449	N/A	
2010	89,846	N/A	93,470	N/A	
2011	87,672	N/A	91,237	N/A	
2012	84,972	N/A	88,358	N/A	
2013	72,538	N/A	75,265	N/A	
Drug Screen in the Prior 30 Days					
2009	7,764	8.1%	7,833	7.9%	
2010	9,695	10.8%	9,797	10.5%	
2011	11,558	13.2%	11,716	12.8%	
2012	13,706	16.1%	13,909	15.7%	
2013	11,155	15.4%	11,315	15.0%	
Drug Screen in the Following 183 Days					
2009	15,503	16.2%	15,862	15.9%	
2010	17,822	19.8%	18,212	19.5%	
2011	20,039	22.9%	20,586	22.6%	

Table 4: Percentage of New Extended-Release and Long-Acting (ER/LA) Opioid Analgesics Users and Episodes with Drug Screens in the Mini-Sentinel Distributed Database (MSDD) between January 1, 2009 and December 31, 2013, by Incidence Assessment Period/Enrollment Requirement, Minimum Days Supplied, Evidence of Prior Immediate Release (IR) Opioid Use, and Year

	New Users	Percentage of New Users with Drug		Percentage of New Episodes with Drug	
		Screen		Screen	
2012	22,350	26.3%		22,917	25.9%
2013	18,525	25.5%		18,984	25.2%
Minimum Days Supplied = 84 Days					
All					
2009	27,735	N/A		27,839	N/A
2010	26,321	N/A		26,408	N/A
2011	26,031	N/A		26,126	N/A
2012	25,576	N/A		25,662	N/A
2013	20,858	N/A		20,937	N/A
Drug Screen in the Prior 30 Days					
2009	3,468	12.5%		3,473	12.5%
2010	4,504	17.1%		4,505	17.1%
2011	5,134	19.7%		5,147	19.7%
2012	5,898	23.1%		5,904	23.0%
2013	4,825	23.1%		4,830	23.1%
Drug Screen in the Following 183 Days					
2009	7,240	26.1%		7,261	26.1%
2010	8,390	31.9%		8,403	31.8%
2011	9,296	35.7%		9,324	35.7%
2012	10,311	40.3%		10,338	40.3%
2013	8,377	40.2%		8,397	40.1%

Appendix for Table 4: Summary of Extended-Release and Long-Acting (ER/LA) Opioid Analgesics Use and Drug Screens in the Mini-Sentinel Distributed Database (MSDD) between January 1, 2009 and December 31, 2013, by Incidence Assessment Period/Enrollment Requirement, Minimum Days Supplied, Immediate Release (IR) Exclusion Requirement, Drug Screen Inclusion Requirement, and Year

	New Users	New Episodes	Dispensings	Days Supplied	Amount Supplied	Eligible Members	Member-Years	New Users/1K Eligible Members	Days Supplied/ User	Dispensings/ User	Days Supplied/ Dispensing
183-day Incidence Assessment Period/Enrollment Requirement (No IR opioid use exclusion requirement)											
<i>Minimum Days Supplied = 1 Day</i>											
All											
2009	115,493	116,370	503,837	13,384,657	30,691,549	42,571,154	32,832,308.7	2.71	115.89	4.36	26.57
2010	108,300	109,124	456,943	12,065,385	26,557,882	40,362,449	31,321,712.0	2.68	111.41	4.22	26.40
2011	105,085	105,865	423,651	11,137,793	22,590,355	38,903,987	30,402,556.4	2.70	105.99	4.03	26.29
2012	101,723	102,476	376,514	9,813,016	19,250,291	37,647,762	29,523,402.3	2.70	96.47	3.70	26.06
2013	87,779	88,406	272,747	6,844,511	12,417,306	36,292,301	28,168,107.2	2.42	77.97	3.11	25.09
Drug Screen in the Prior 30 Days											
2009	7,330	7,342	54,245	1,494,956	3,267,881	N/A	N/A	N/A	203.95	7.40	27.56
2010	9,090	9,111	67,241	1,853,099	4,048,116	N/A	N/A	N/A	203.86	7.40	27.56
2011	10,859	10,889	71,166	1,955,484	4,128,151	N/A	N/A	N/A	180.08	6.55	27.48
2012	12,887	12,933	69,793	1,913,266	3,743,540	N/A	N/A	N/A	148.46	5.42	27.41
2013	10,269	10,290	50,542	1,354,875	2,487,176	N/A	N/A	N/A	131.94	4.92	26.81
Drug Screen in the Following 183 Days											
2009	14,706	14,755	113,460	3,109,323	7,222,949	N/A	N/A	N/A	211.43	7.72	27.40
2010	16,866	16,930	126,762	3,502,552	7,813,481	N/A	N/A	N/A	207.67	7.52	27.63
2011	18,985	19,078	129,295	3,560,529	7,542,438	N/A	N/A	N/A	187.54	6.81	27.54
2012	21,141	21,212	125,231	3,429,390	6,922,347	N/A	N/A	N/A	162.22	5.92	27.38
2013	17,334	17,404	87,148	2,340,994	4,285,474	N/A	N/A	N/A	135.05	5.03	26.86
Minimum Days Supplied = 84 Days											
All											
2009	26,756	26,760	380,665	10,879,776	25,964,516	40,259,262	30,341,666.1	0.66	406.63	14.23	28.58
2010	24,982	24,994	341,704	9,731,871	22,197,920	38,358,529	29,043,530.3	0.65	389.56	13.68	28.48
2011	24,593	24,601	312,945	8,871,606	18,627,828	37,073,817	28,264,241.2	0.66	360.74	12.72	28.35
2012	23,949	23,959	269,752	7,624,153	15,413,814	35,845,880	27,364,289.2	0.67	318.35	11.26	28.26
2013	19,467	19,469	179,344	4,974,724	9,302,694	34,495,970	25,782,920.5	0.56	255.55	9.21	27.74
Drug Screen in the Prior 30 Days											
2009	3,151	3,151	47,829	1,347,317	2,986,779	N/A	N/A	N/A	427.58	15.18	28.17
2010	4,072	4,072	59,687	1,675,659	3,712,342	N/A	N/A	N/A	411.51	14.66	28.07
2011	4,640	4,640	61,803	1,731,067	3,737,509	N/A	N/A	N/A	373.07	13.32	28.01
2012	5,277	5,277	58,577	1,640,766	3,277,846	N/A	N/A	N/A	310.93	11.10	28.01
2013	4,257	4,257	41,436	1,137,601	2,151,708	N/A	N/A	N/A	267.23	9.73	27.45
Drug Screen in the Following 183 Days											
2009	6,600	6,600	100,904	2,819,191	6,650,547	N/A	N/A	N/A	427.15	15.29	27.94
2010	7,686	7,689	112,791	3,174,776	7,188,547	N/A	N/A	N/A	413.06	14.67	28.15
2011	8,447	8,449	113,335	3,181,105	6,871,340	N/A	N/A	N/A	376.60	13.42	28.07
2012	9,311	9,314	107,490	3,003,144	6,185,664	N/A	N/A	N/A	322.54	11.54	27.94
2013	7,438	7,438	72,175	1,987,394	3,712,512	N/A	N/A	N/A	267.19	9.70	27.54
90-day Incidence Assessment Period/Enrollment Requirement (No IR opioid use exclusion requirement)											
<i>Minimum Days Supplied = 1 Day</i>											
All											
2009	134,591	139,415	614,178	16,414,485	38,345,797	45,860,980	35,655,184.5	2.93	121.96	4.56	26.73
2010	125,744	130,176	554,105	14,726,955	32,884,293	43,604,978	33,918,222.0	2.88	117.12	4.41	26.58
2011	122,115	126,455	516,004	13,658,480	28,287,377	42,083,174	32,920,405.0	2.90	111.85	4.23	26.47
2012	118,207	122,345	458,555	12,041,546	23,997,552	40,747,245	31,920,844.5	2.90	101.87	3.88	26.26
2013	102,700	106,077	335,096	8,500,687	15,812,585	39,271,856	30,570,887.2	2.62	82.77	3.26	25.37
Drug Screen in the Prior 30 Days											
2009	9,020	9,093	67,002	1,843,573	4,121,384	N/A	N/A	N/A	204.39	7.43	27.52



2010	11,087	11,195	82,383	2,274,083	5,023,571	N/A	N/A	N/A	205.11	7.43	27.60
2011	13,227	13,394	88,084	2,418,886	5,158,706	N/A	N/A	N/A	182.87	6.66	27.46
2012	15,750	15,964	87,306	2,394,129	4,745,904	N/A	N/A	N/A	152.01	5.54	27.42
2013	12,879	13,047	64,108	1,722,640	3,244,959	N/A	N/A	N/A	133.76	4.98	26.87
Drug Screen in the Following 183 Days											
2009	18,278	18,664	141,946	3,885,657	9,134,815	N/A	N/A	N/A	212.59	7.77	27.37
2010	20,640	21,057	155,358	4,288,074	9,715,570	N/A	N/A	N/A	207.76	7.53	27.60
2011	23,185	23,759	160,503	4,421,096	9,549,766	N/A	N/A	N/A	190.69	6.92	27.55
2012	25,879	26,485	155,913	4,276,116	8,717,916	N/A	N/A	N/A	165.23	6.02	27.43
2013	21,677	22,167	111,395	3,000,041	5,633,522	N/A	N/A	N/A	138.40	5.14	26.93
90-day Incidence Assessment Period/Enrollment Requirement (No IR opioid use exclusion requirement)											
Minimum Days Supplied = 84 Days											
All											
2009	33,063	33,184	468,035	13,387,992	32,477,113	43,213,237	32,909,563.8	0.77	404.92	14.16	28.60
2010	30,890	30,996	418,156	11,921,364	27,511,831	41,280,376	31,416,803.0	0.75	385.93	13.54	28.51
2011	30,299	30,411	384,907	10,924,809	23,387,168	39,944,631	30,564,149.8	0.76	360.57	12.70	28.38
2012	29,622	29,720	332,475	9,407,867	19,291,014	38,580,301	29,543,801.0	0.77	317.60	11.22	28.30
2013	24,337	24,426	224,384	6,237,412	11,949,291	37,181,908	27,947,744.2	0.65	256.29	9.22	27.80
Drug Screen in the Prior 30 Days											
2009	3,893	3,898	59,040	1,659,785	3,763,476	N/A	N/A	N/A	426.35	15.17	28.11
2010	5,017	5,018	73,070	2,054,774	4,601,746	N/A	N/A	N/A	409.56	14.56	28.12
2011	5,734	5,747	76,583	2,144,025	4,674,911	N/A	N/A	N/A	373.91	13.36	28.00
2012	6,587	6,594	73,504	2,059,715	4,168,523	N/A	N/A	N/A	312.69	11.16	28.02
2013	5,409	5,414	52,572	1,446,639	2,807,588	N/A	N/A	N/A	267.45	9.72	27.52
Drug Screen in the Following 183 Days											
2009	8,302	8,323	126,044	3,515,877	8,384,216	N/A	N/A	N/A	423.50	15.18	27.89
2010	9,536	9,550	137,944	3,878,443	8,913,149	N/A	N/A	N/A	406.72	14.47	28.12
2011	10,481	10,510	140,558	3,945,036	8,688,209	N/A	N/A	N/A	376.40	13.41	28.07
2012	11,625	11,654	133,826	3,742,299	7,778,852	N/A	N/A	N/A	321.92	11.51	27.96
2013	9,514	9,535	92,480	2,549,973	4,885,907	N/A	N/A	N/A	268.02	9.72	27.57
183-day Incidence Assessment Period/Enrollment Requirement (IR opioid use exclusion requirement)											
Minimum Days Supplied = 1 Day											
All											
2009	32,672	32,812	86,215	2,045,419	5,340,762	42,088,338	31,132,674.4	0.78	62.60	2.64	23.72
2010	30,156	30,285	73,745	1,726,651	4,390,034	39,881,465	29,691,519.0	0.76	57.26	2.45	23.41
2011	28,936	29,081	67,958	1,556,504	3,515,423	38,423,577	28,831,535.3	0.75	53.79	2.35	22.90
2012	28,024	28,169	60,819	1,362,099	3,083,790	37,176,119	28,021,140.2	0.75	48.60	2.17	22.40
2013	25,321	25,454	48,581	1,027,940	2,155,333	35,841,727	26,796,634.0	0.71	40.60	1.92	21.16
Drug Screen in the Prior 30 Days											
2009	936	937	5,691	147,197	396,369	N/A	N/A	N/A	157.26	6.08	25.86
2010	1,031	1,032	6,134	163,524	437,215	N/A	N/A	N/A	158.61	5.95	26.66
2011	1,260	1,261	6,627	176,404	475,203	N/A	N/A	N/A	140.00	5.26	26.62
2012	1,518	1,520	6,683	178,868	416,794	N/A	N/A	N/A	117.83	4.40	26.76
2013	1,237	1,238	5,105	134,698	320,934	N/A	N/A	N/A	108.89	4.13	26.39
Drug Screen in the Following 183 Days											
2009	2,018	2,024	13,059	346,264	1,028,303	N/A	N/A	N/A	171.59	6.47	26.52
2010	2,064	2,066	13,719	370,528	986,534	N/A	N/A	N/A	179.52	6.65	27.01
2011	2,286	2,292	13,453	360,793	950,953	N/A	N/A	N/A	157.83	5.88	26.82
2012	2,555	2,559	12,917	345,098	896,221	N/A	N/A	N/A	135.07	5.06	26.72
2013	2,245	2,250	9,382	245,287	574,087	N/A	N/A	N/A	109.26	4.18	26.14
Minimum Days Supplied = 84 Days											
All											
2009	3,813	3,814	50,138	1,424,692	4,057,454	39,785,649	28,772,413.9	0.10	373.64	13.15	28.42
2010	3,195	3,195	40,423	1,161,152	3,230,918	37,882,398	27,534,238.3	0.08	363.43	12.65	28.73
2011	3,052	3,054	35,970	1,013,595	2,460,795	36,598,031	26,807,375.7	0.08	332.11	11.79	28.18
2012	2,820	2,821	29,705	836,545	2,072,158	35,376,375	25,984,062.6	0.08	296.65	10.53	28.16
2013	2,370	2,370	20,525	572,426	1,307,022	34,048,883	24,530,947.9	0.07	241.53	8.66	27.89

Drug Screen in the Prior 30 Days

2009	309	309	4,752	128,160	355,940	N/A	N/A	N/A	414.76	15.38	26.97
2010	351	351	5,193	143,404	395,203	N/A	N/A	N/A	408.56	14.79	27.61
2011	423	423	5,427	149,222	418,668	N/A	N/A	N/A	352.77	12.83	27.50
2012	492	492	5,225	145,204	352,192	N/A	N/A	N/A	295.13	10.62	27.79
2013	402	402	3,898	106,999	270,696	N/A	N/A	N/A	266.17	9.70	27.45

Drug Screen in the Following 183 Days

2009	738	738	11,092	304,824	931,363	N/A	N/A	N/A	413.04	15.03	27.48
2010	797	797	11,881	331,014	897,927	N/A	N/A	N/A	415.32	14.91	27.86
2011	832	832	11,357	314,594	851,609	N/A	N/A	N/A	378.12	13.65	27.70
2012	920	921	10,501	290,394	786,796	N/A	N/A	N/A	315.65	11.41	27.65
2013	753	753	7,160	196,756	481,102	N/A	N/A	N/A	261.30	9.51	27.48

90-day Incidence Assessment Period/Enrollment Requirement (IR opioid use exclusion requirement)

Minimum Days Supplied = 1 Day

All

2009	39,089	39,966	113,115	2,774,083	7,588,058	45,359,426	33,813,487.2	0.86	70.97	2.89	24.52
2010	35,898	36,706	96,856	2,360,992	6,134,801	43,103,737	32,159,530.8	0.83	65.77	2.70	24.38
2011	34,443	35,218	88,332	2,111,087	5,021,638	41,580,912	31,221,876.1	0.83	61.29	2.56	23.90
2012	33,235	33,987	79,892	1,873,930	4,425,139	40,250,540	30,297,967.4	0.83	56.38	2.40	23.46
2013	30,162	30,812	63,697	1,421,791	3,162,634	38,808,438	29,084,174.7	0.78	47.14	2.11	22.32

Drug Screen in the Prior 30 Days

2009	1,256	1,260	7,658	200,544	582,009	N/A	N/A	N/A	159.67	6.10	26.19
2010	1,392	1,398	8,807	240,846	656,833	N/A	N/A	N/A	173.02	6.33	27.35
2011	1,669	1,678	9,421	250,901	696,537	N/A	N/A	N/A	150.33	5.64	26.63
2012	2,044	2,055	9,320	251,658	628,337	N/A	N/A	N/A	123.12	4.56	27.00
2013	1,724	1,732	7,365	196,650	488,134	N/A	N/A	N/A	114.07	4.27	26.70

Drug Screen in the Following 183 Days

2009	2,775	2,802	18,537	495,441	1,500,247	N/A	N/A	N/A	178.54	6.68	26.73
2010	2,818	2,845	19,039	518,702	1,421,682	N/A	N/A	N/A	184.07	6.76	27.24
2011	3,146	3,173	19,128	514,535	1,406,345	N/A	N/A	N/A	163.55	6.08	26.90
2012	3,529	3,568	18,482	498,459	1,296,555	N/A	N/A	N/A	141.25	5.24	26.97
2013	3,152	3,183	13,909	368,717	911,285	N/A	N/A	N/A	116.98	4.41	26.51

Minimum Days Supplied = 84 Days

All

2009	5,328	5,345	69,882	1,996,321	5,899,356	42,724,405	31,212,022.4	0.12	374.68	13.12	28.57
2010	4,569	4,588	57,090	1,653,733	4,622,380	40,789,374	29,790,784.7	0.11	361.95	12.50	28.97
2011	4,268	4,285	50,142	1,431,526	3,639,793	39,451,890	28,991,681.7	0.11	335.41	11.75	28.55
2012	4,046	4,058	43,000	1,219,830	3,108,247	38,094,201	28,055,385.9	0.11	301.49	10.63	28.37
2013	3,479	3,489	30,297	851,421	2,050,384	36,725,100	26,592,672.0	0.09	244.73	8.71	28.10

Drug Screen in the Prior 30 Days

2009	425	425	6,415	174,525	522,932	N/A	N/A	N/A	410.65	15.09	27.21
2010	513	513	7,550	213,616	597,748	N/A	N/A	N/A	416.41	14.72	28.29
2011	600	600	7,868	215,375	620,861	N/A	N/A	N/A	358.96	13.11	27.37
2012	689	690	7,371	206,139	539,712	N/A	N/A	N/A	299.19	10.70	27.97
2013	584	584	5,703	158,079	414,604	N/A	N/A	N/A	270.68	9.77	27.72

Drug Screen in the Following 183 Days

2009	1,062	1,062	15,890	438,416	1,358,980	N/A	N/A	N/A	412.82	14.96	27.59
2010	1,146	1,147	16,540	463,555	1,289,167	N/A	N/A	N/A	404.50	14.43	28.03
2011	1,185	1,186	16,257	449,579	1,259,912	N/A	N/A	N/A	379.39	13.72	27.65
2012	1,314	1,316	15,187	421,803	1,136,181	N/A	N/A	N/A	321.01	11.56	27.77
2013	1,137	1,138	10,913	301,167	773,278	N/A	N/A	N/A	264.88	9.60	27.60

Appendix A: List of Drugs used for Exposures in this Request

Generic Name	Brand Name	Route	Form	Strength	Unit
Extended-Release and Long-Acting (ER/LA) Opioid Analgesics					
BUPRENORPHINE	Butrans	transdermal	patch weekly	10	mcg/hour
BUPRENORPHINE	Butrans	transdermal	patch weekly	15	mcg/hour
BUPRENORPHINE	Butrans	transdermal	patch weekly	20	mcg/hour
BUPRENORPHINE	Butrans	transdermal	patch weekly	5	mcg/hour
BUPRENORPHINE	Butrans	transdermal	patch weekly	7.5	mcg/hour
FENTANYL	Duragesic	transdermal	patch 72 hour	100	mcg/hr
FENTANYL	fentanyl	transdermal	patch 72 hour	100	mcg/hr
FENTANYL	Duragesic	transdermal	patch 72 hour	12	mcg/hr
FENTANYL	fentanyl	transdermal	patch 72 hour	12	mcg/hr
FENTANYL	Duragesic	transdermal	patch 72 hour	25	mcg/hr
FENTANYL	fentanyl	transdermal	patch 72 hour	25	mcg/hr
FENTANYL	Duragesic	transdermal	patch 72 hour	50	mcg/hr
FENTANYL	fentanyl	transdermal	patch 72 hour	50	mcg/hr
FENTANYL	Duragesic	transdermal	patch 72 hour	75	mcg/hr
FENTANYL	fentanyl	transdermal	patch 72 hour	75	mcg/hr
HYDROCODONE BITARTRATE	Zohydro ER	oral	capsule,extended release 12 hr	10	mg
HYDROCODONE BITARTRATE	Hysingla ER	oral	tablet,oral only,ext.rel.24 hr	100	mg
HYDROCODONE BITARTRATE	Hysingla ER	oral	tablet,oral only,ext.rel.24 hr	120	mg
HYDROCODONE BITARTRATE	Zohydro ER	oral	capsule,extended release 12 hr	15	mg
HYDROCODONE BITARTRATE	Hysingla ER	oral	tablet,oral only,ext.rel.24 hr	20	mg
HYDROCODONE BITARTRATE	Zohydro ER	oral	capsule,extended release 12 hr	20	mg
HYDROCODONE BITARTRATE	Hysingla ER	oral	tablet,oral only,ext.rel.24 hr	30	mg
HYDROCODONE BITARTRATE	Zohydro ER	oral	capsule,extended release 12 hr	30	mg
HYDROCODONE BITARTRATE	Hysingla ER	oral	tablet,oral only,ext.rel.24 hr	40	mg
HYDROCODONE BITARTRATE	Zohydro ER	oral	capsule,extended release 12 hr	40	mg
HYDROCODONE BITARTRATE	Zohydro ER	oral	capsule,extended release 12 hr	50	mg
HYDROCODONE BITARTRATE	Hysingla ER	oral	tablet,oral only,ext.rel.24 hr	60	mg
HYDROCODONE BITARTRATE	Hysingla ER	oral	tablet,oral only,ext.rel.24 hr	80	mg
HYDROMORPHONE HCL	Exalgo ER	oral	tablet extended release 24 hr	12	mg
HYDROMORPHONE HCL	hydromorphone	oral	tablet extended release 24 hr	12	mg

Generic Name	Brand Name	Route	Form	Strength	Unit
HYDROMORPHONE HCL	Palladone	oral	capsule,ext rel. pellets 24 hr	12	mg
HYDROMORPHONE HCL	Exalgo ER	oral	tablet extended release 24 hr	16	mg
HYDROMORPHONE HCL	hydromorphone	oral	tablet extended release 24 hr	16	mg
HYDROMORPHONE HCL	Palladone	oral	capsule,ext rel. pellets 24 hr	16	mg
HYDROMORPHONE HCL	Palladone	oral	capsule,ext rel. pellets 24 hr	24	mg
HYDROMORPHONE HCL	Exalgo ER	oral	tablet extended release 24 hr	32	mg
HYDROMORPHONE HCL	hydromorphone	oral	tablet extended release 24 hr	32	mg
HYDROMORPHONE HCL	Palladone	oral	capsule,ext rel. pellets 24 hr	32	mg
HYDROMORPHONE HCL	Exalgo ER	oral	tablet extended release 24 hr	8	mg
HYDROMORPHONE HCL	hydromorphone	oral	tablet extended release 24 hr	8	mg
METHADONE HCL	Dolophine	oral	tablet	10	mg
METHADONE HCL	methadone	oral	tablet	10	mg
METHADONE HCL	Methadose	oral	tablet	10	mg
METHADONE HCL	methadone	oral	solution	10	mg/5 mL
METHADONE HCL	methadone	oral	concentrate	10	mg/mL
METHADONE HCL	methadone	oral	syringe	10	mg/mL
METHADONE HCL	Methadone Intensol	oral	concentrate	10	mg/mL
METHADONE HCL	Methadose	oral	concentrate	10	mg/mL
METHADONE HCL	Diskets	oral	tablet,soluble	40	mg
METHADONE HCL	methadone	oral	tablet,soluble	40	mg
METHADONE HCL	Methadose	oral	tablet,soluble	40	mg
METHADONE HCL	Dolophine	oral	tablet	5	mg
METHADONE HCL	methadone	oral	tablet	5	mg
METHADONE HCL	Methadose	oral	tablet	5	mg
METHADONE HCL	methadone	oral	solution	5	mg/5 mL
METHADONE HCL	methadone	oral	syringe	5	mg/5 mL
MORPHINE SULFATE	Kadian	oral	capsule,extend.release pellets	10	mg
MORPHINE SULFATE	morphine	oral	capsule,extend.release pellets	10	mg
MORPHINE SULFATE	Kadian	oral	capsule,extend.release pellets	100	mg
MORPHINE SULFATE	morphine	oral	tablet extended release	100	mg
MORPHINE SULFATE	morphine	oral	capsule,extend.release pellets	100	mg
MORPHINE SULFATE	MS Contin	oral	tablet extended release	100	mg
MORPHINE SULFATE	Oramorph SR	oral	tablet extended release	100	mg
MORPHINE SULFATE	Avinza	oral	capsule, ER multiphase 24 hr	120	mg

Generic Name	Brand Name	Route	Form	Strength	Unit
MORPHINE SULFATE	morphine	oral	capsule, ER multiphase 24 hr	120	mg
MORPHINE SULFATE	Kadian	oral	capsule,extend.release pellets	130	mg
MORPHINE SULFATE	morphine	oral	tablet extended release	15	mg
MORPHINE SULFATE	MS Contin	oral	tablet extended release	15	mg
MORPHINE SULFATE	Oramorph SR	oral	tablet extended release	15	mg
MORPHINE SULFATE	Kadian	oral	capsule,extend.release pellets	150	mg
MORPHINE SULFATE	Kadian	oral	capsule,extend.release pellets	20	mg
MORPHINE SULFATE	morphine	oral	capsule,extend.release pellets	20	mg
MORPHINE SULFATE	Kadian	oral	capsule,extend.release pellets	200	mg
MORPHINE SULFATE	morphine	oral	tablet extended release	200	mg
MORPHINE SULFATE	MS Contin	oral	tablet extended release	200	mg
MORPHINE SULFATE	Avinza	oral	capsule, ER multiphase 24 hr	30	mg
MORPHINE SULFATE	Kadian	oral	capsule,extend.release pellets	30	mg
MORPHINE SULFATE	morphine	oral	capsule,extend.release pellets	30	mg
MORPHINE SULFATE	morphine	oral	tablet extended release	30	mg
MORPHINE SULFATE	morphine	oral	capsule, ER multiphase 24 hr	30	mg
MORPHINE SULFATE	MS Contin	oral	tablet extended release	30	mg
MORPHINE SULFATE	Oramorph SR	oral	tablet extended release	30	mg
MORPHINE SULFATE	Kadian	oral	capsule,extend.release pellets	40	mg
MORPHINE SULFATE	Avinza	oral	capsule, ER multiphase 24 hr	45	mg
MORPHINE SULFATE	morphine	oral	capsule, ER multiphase 24 hr	45	mg
MORPHINE SULFATE	Kadian	oral	capsule,extend.release pellets	50	mg
MORPHINE SULFATE	morphine	oral	capsule,extend.release pellets	50	mg
MORPHINE SULFATE	Avinza	oral	capsule, ER multiphase 24 hr	60	mg
MORPHINE SULFATE	Kadian	oral	capsule,extend.release pellets	60	mg
MORPHINE SULFATE	morphine	oral	tablet extended release	60	mg
MORPHINE SULFATE	morphine	oral	capsule,extend.release pellets	60	mg
MORPHINE SULFATE	morphine	oral	capsule, ER multiphase 24 hr	60	mg
MORPHINE SULFATE	MS Contin	oral	tablet extended release	60	mg
MORPHINE SULFATE	Oramorph SR	oral	tablet extended release	60	mg
MORPHINE SULFATE	Kadian	oral	capsule,extend.release pellets	70	mg
MORPHINE SULFATE	Avinza	oral	capsule, ER multiphase 24 hr	75	mg
MORPHINE SULFATE	morphine	oral	capsule, ER multiphase 24 hr	75	mg

Generic Name	Brand Name	Route	Form	Strength	Unit
MORPHINE SULFATE	Kadian	oral	capsule,extend.release pellets	80	mg
MORPHINE SULFATE	morphine	oral	capsule,extend.release pellets	80	mg
MORPHINE SULFATE	Avinza	oral	capsule, ER multiphase 24 hr	90	mg
MORPHINE SULFATE	morphine	oral	capsule, ER multiphase 24 hr	90	mg
MORPHINE SULFATE/NALTREXONE HCL	Embeda	oral	capsule,oral only,ext.rel pell	100-4	mg
MORPHINE SULFATE/NALTREXONE HCL	Embeda	oral	capsule,extend.release pellets	100-4	mg
MORPHINE SULFATE/NALTREXONE HCL	Embeda	oral	capsule,extend.release pellets	20-0.8	mg
MORPHINE SULFATE/NALTREXONE HCL	Embeda	oral	capsule,oral only,ext.rel pell	20-0.8	mg
MORPHINE SULFATE/NALTREXONE HCL	Embeda	oral	capsule,extend.release pellets	30-1.2	mg
MORPHINE SULFATE/NALTREXONE HCL	Embeda	oral	capsule,oral only,ext.rel pell	30-1.2	mg
MORPHINE SULFATE/NALTREXONE HCL	Embeda	oral	capsule,oral only,ext.rel pell	50-2	mg
MORPHINE SULFATE/NALTREXONE HCL	Embeda	oral	capsule,extend.release pellets	50-2	mg
MORPHINE SULFATE/NALTREXONE HCL	Embeda	oral	capsule,extend.release pellets	60-2.4	mg
MORPHINE SULFATE/NALTREXONE HCL	Embeda	oral	capsule,oral only,ext.rel pell	60-2.4	mg
MORPHINE SULFATE/NALTREXONE HCL	Embeda	oral	capsule,oral only,ext.rel pell	80-3.2	mg
MORPHINE SULFATE/NALTREXONE HCL	Embeda	oral	capsule,extend.release pellets	80-3.2	mg
OXYCODONE HCL	oxycodone	oral	tablet extended release 12 hr	10	mg
OXYCODONE HCL	oxycodone	oral	tablet,oral only,ext.rel.12 hr	10	mg
OXYCODONE HCL	OxyContin	oral	tablet extended release 12 hr	10	mg
OXYCODONE HCL	OxyContin	oral	tablet,oral only,ext.rel.12 hr	10	mg
OXYCODONE HCL	OxyContin	oral	tablet extended release 12 hr	15	mg
OXYCODONE HCL	OxyContin	oral	tablet,oral only,ext.rel.12 hr	15	mg
OXYCODONE HCL	OxyContin	oral	tablet extended release 12 hr	160	mg
OXYCODONE HCL	oxycodone	oral	tablet extended release 12 hr	20	mg
OXYCODONE HCL	oxycodone	oral	tablet,oral only,ext.rel.12 hr	20	mg
OXYCODONE HCL	OxyContin	oral	tablet extended release 12 hr	20	mg
OXYCODONE HCL	OxyContin	oral	tablet,oral only,ext.rel.12 hr	20	mg
OXYCODONE HCL	OxyContin	oral	tablet extended release 12 hr	30	mg
OXYCODONE HCL	OxyContin	oral	tablet,oral only,ext.rel.12 hr	30	mg
OXYCODONE HCL	oxycodone	oral	tablet extended release 12 hr	40	mg
OXYCODONE HCL	oxycodone	oral	tablet,oral only,ext.rel.12 hr	40	mg
OXYCODONE HCL	OxyContin	oral	tablet,oral only,ext.rel.12 hr	40	mg
OXYCODONE HCL	OxyContin	oral	tablet extended release 12 hr	40	mg

Generic Name	Brand Name	Route	Form	Strength	Unit
OXYCODONE HCL	OxyContin	oral	tablet extended release 12 hr	60	mg
OXYCODONE HCL	OxyContin	oral	tablet,oral only,ext.rel.12 hr	60	mg
OXYCODONE HCL	oxycodone	oral	tablet extended release 12 hr	80	mg
OXYCODONE HCL	oxycodone	oral	tablet,oral only,ext.rel.12 hr	80	mg
OXYCODONE HCL	OxyContin	oral	tablet extended release 12 hr	80	mg
OXYCODONE HCL	OxyContin	oral	tablet,oral only,ext.rel.12 hr	80	mg
OXYMORPHONE HCL	Opana ER	oral	tablet extended release 12 hr	10	mg
OXYMORPHONE HCL	Opana ER	oral	tablet,oral only,ext.rel.12 hr	10	mg
OXYMORPHONE HCL	oxymorphone	oral	tablet extended release 12 hr	10	mg
OXYMORPHONE HCL	Opana ER	oral	tablet extended release 12 hr	15	mg
OXYMORPHONE HCL	Opana ER	oral	tablet,oral only,ext.rel.12 hr	15	mg
OXYMORPHONE HCL	oxymorphone	oral	tablet extended release 12 hr	15	mg
OXYMORPHONE HCL	Opana ER	oral	tablet,oral only,ext.rel.12 hr	20	mg
OXYMORPHONE HCL	Opana ER	oral	tablet extended release 12 hr	20	mg
OXYMORPHONE HCL	oxymorphone	oral	tablet extended release 12 hr	20	mg
OXYMORPHONE HCL	Opana ER	oral	tablet,oral only,ext.rel.12 hr	30	mg
OXYMORPHONE HCL	Opana ER	oral	tablet extended release 12 hr	30	mg
OXYMORPHONE HCL	oxymorphone	oral	tablet extended release 12 hr	30	mg
OXYMORPHONE HCL	Opana ER	oral	tablet extended release 12 hr	40	mg
OXYMORPHONE HCL	Opana ER	oral	tablet,oral only,ext.rel.12 hr	40	mg
OXYMORPHONE HCL	oxymorphone	oral	tablet extended release 12 hr	40	mg
OXYMORPHONE HCL	Opana ER	oral	tablet,oral only,ext.rel.12 hr	5	mg
OXYMORPHONE HCL	Opana ER	oral	tablet extended release 12 hr	5	mg
OXYMORPHONE HCL	oxymorphone	oral	tablet extended release 12 hr	5	mg
OXYMORPHONE HCL	Opana ER	oral	tablet,oral only,ext.rel.12 hr	7.5	mg
OXYMORPHONE HCL	Opana ER	oral	tablet extended release 12 hr	7.5	mg
OXYMORPHONE HCL	oxymorphone	oral	tablet extended release 12 hr	7.5	mg
TAPENTADOL HCL	Nucynta ER	oral	tablet extended release 12 hr	100	mg
TAPENTADOL HCL	Nucynta ER	oral	tablet extended release 12 hr	150	mg
TAPENTADOL HCL	Nucynta ER	oral	tablet extended release 12 hr	200	mg
TAPENTADOL HCL	Nucynta ER	oral	tablet extended release 12 hr	250	mg
TAPENTADOL HCL	Nucynta ER	oral	tablet extended release 12 hr	50	mg

Appendix B: List of Healthcare Common Procedure Coding System (HCPCS) and Current Procedural Terminology, Fourth Revision (CPT-4) Procedure Codes used for Drug Screens in this Request

Code	Description	Code Type	Care Setting
Drug Screens			
G0430	Drug screen, qualitative; multiple drug classes, other than chromatographic method, each procedure	HCPCS	Any
G0431	Drug screen, qualitative; single drug class method (e.g., immunoassay, and enzyme assay), each drug class	HCPCS	Any
G0434	Drug screen, other than chromatographic; any number of drug classes, by CLIA waived test or moderate complexity test, per patient encounter	HCPCS	Any
80100	Drug screen, qualitative; multiple drug classes chromatographic method, each procedure	CPT-4	Any
80101	Drug screen, qualitative; single drug class method (eg, immunoassay, enzyme assay), each drug class	CPT-4	Any
80104	Drug screen, qualitative; multiple drug classes, other than chromatographic method, each procedure	CPT-4	Any
82486	Chromatography, qualitative; column (eg, gas liquid or HPLC), analyte not elsewhere specified	CPT-4	Any
82491	Chromatography, quantitative, column (eg, gas liquid or HPLC); single analyte not elsewhere specified, single stationary and mobile phase	CPT-4	Any
82492	Chromatography, quantitative, column (eg, gas liquid or HPLC); multiple analytes, single stationary and mobile phase	CPT-4	Any
82541	Column chromatography/mass spectrometry (eg, GC/MS, or HPLC/MS), analyte not elsewhere specified; qualitative, single stationary and mobile phase	CPT-4	Any
82542	Column chromatography/mass spectrometry (eg, GC/MS, or HPLC/MS), analyte not elsewhere specified; quantitative, single stationary and mobile phase	CPT-4	Any
82543	Column chromatography/mass spectrometry (eg, GC/MS, or HPLC/MS), analyte not elsewhere specified; stable isotope dilution, single analyte, quantitative, single stationary and mobile phase	CPT-4	Any
82544	Column chromatography/mass spectrometry (eg, GC/MS, or HPLC/MS), analyte not elsewhere specified; stable isotope dilution, multiple analytes, quantitative, single stationary and mobile phase	CPT-4	Any
83788	Mass spectrometry and tandem mass spectrometry (MS, MS/MS), analyte not elsewhere specified; qualitative, each specimen	CPT-4	Any
83789	Mass spectrometry and tandem mass spectrometry (MS, MS/MS), analyte not elsewhere specified; quantitative, each specimen	CPT-4	Any
83925	Opiate(s), drug and metabolites, each procedure	CPT-4	Any

Appendix C1. List of International Classification of Diseases, Ninth Edition, Clinical Modification (ICD-9-CM) Diagnosis Codes used for Exclusions in this Request

Code	Description	Code Type	Care Setting
Opioid Poisoning			
965.0	Poisoning by opiates and related narcotics	ICD-9-CM Diagnosis Code	Inpatient or Outpatient
965.00	Poisoning by opium (alkaloids), unspecified	ICD-9-CM Diagnosis Code	Inpatient or Outpatient
965.01	Poisoning by heroin	ICD-9-CM Diagnosis Code	Inpatient or Outpatient
965.02	Poisoning by methadone	ICD-9-CM Diagnosis Code	Inpatient or Outpatient
965.09	Poisoning by other opiates and related narcotics	ICD-9-CM Diagnosis Code	Inpatient or Outpatient

Appendix C2. List of Drugs used for Inclusions/Exclusions in this Request

Generic Name	Brand Name	Route	Form	Strength	Unit
IR Opioid Analgesics					
ACETAMINOPHEN WITH CODEINE PHOSPHATE	acetaminophen-codeine	oral	solution	120 mg-12 mg	/5 mL (5 mL)
ACETAMINOPHEN WITH CODEINE PHOSPHATE	acetaminophen-codeine	oral	solution	120-12	mg/5 mL
ACETAMINOPHEN WITH CODEINE PHOSPHATE	acetaminophen-codeine	oral	elixir	120-12	mg/5 mL
ACETAMINOPHEN WITH CODEINE PHOSPHATE	Capital with Codeine	oral	suspension	120-12	mg/5 mL
ACETAMINOPHEN WITH CODEINE PHOSPHATE	Tylenol-Codeine Elixir	oral	elixir	120-12	mg/5 mL
ACETAMINOPHEN WITH CODEINE PHOSPHATE	acetaminophen-codeine	oral	solution	240 mg-24 mg	/10 mL (10 mL)
ACETAMINOPHEN WITH CODEINE PHOSPHATE	acetaminophen-codeine	oral	solution	300 mg-30 mg	/12.5 mL
ACETAMINOPHEN WITH CODEINE PHOSPHATE	acetaminophen-codeine	oral	tablet	300-15	mg
ACETAMINOPHEN WITH CODEINE PHOSPHATE	acetaminophen-codeine	oral	tablet	300-30	mg
ACETAMINOPHEN WITH CODEINE PHOSPHATE	Tylenol-Codeine #3	oral	tablet	300-30	mg
ACETAMINOPHEN WITH CODEINE PHOSPHATE	acetaminophen-codeine	oral	tablet	300-60	mg
ACETAMINOPHEN WITH CODEINE PHOSPHATE	Tylenol-Codeine #4	oral	tablet	300-60	mg
ACETAMINOPHEN WITH CODEINE PHOSPHATE	Phenaphen/Codeine #3	oral	capsule	325-30	mg
ACETAMINOPHEN WITH CODEINE PHOSPHATE	Phenaphen/Codeine #4	oral	capsule	325-60	mg
ACETAMINOPHEN WITH CODEINE PHOSPHATE	acetaminophen-codeine	oral	solution	360 mg-36 mg	/15 mL (15 mL)
ACETAMINOPHEN WITH CODEINE PHOSPHATE	Cocet	oral	tablet	650-30	mg
ACETAMINOPHEN WITH CODEINE PHOSPHATE	Vopac	oral	tablet	650-30	mg
ACETAMINOPHEN WITH CODEINE PHOSPHATE	Cocet Plus	oral	tablet	650-60	mg
ASPIRIN/CODEINE PHOSPHATE	aspirin-codeine	oral	tablet	325-30	mg
ASPIRIN/CODEINE PHOSPHATE	Aspirin-Codeine #3	oral	tablet	325-30	mg
ASPIRIN/CODEINE PHOSPHATE	Aspirin-Codeine #4	oral	tablet	325-60	mg
BUTALBITAL/ACETAMINOPHEN/CAFFEINE/CODEINE PHOSPHATE	butalbital-acetaminop-caf-cod	oral	capsule	50-300-40-30	mg
BUTALBITAL/ACETAMINOPHEN/CAFFEINE/CODEINE PHOSPHATE	Fioricet with Codeine	oral	capsule	50-300-40-30	mg
BUTALBITAL/ACETAMINOPHEN/CAFFEINE/CODEINE PHOSPHATE	butalbital-acetaminop-caf-cod	oral	capsule	50-325-40-30	mg
BUTALBITAL/ACETAMINOPHEN/CAFFEINE/CODEINE PHOSPHATE	Fioricet with Codeine	oral	capsule	50-325-40-30	mg
BUTALBITAL/ACETAMINOPHEN/CAFFEINE/CODEINE PHOSPHATE	Phrenilin w/Caffeine-Codeine	oral	capsule	50-325-40-30	mg

Generic Name	Brand Name	Route	Form	Strength	Unit
CODEINE PHOSPHATE	codeine phosphate Ascomp with Codeine	oral	solution	15	mg/5 mL
CODEINE PHOSPHATE/BUTALBITAL/ASPIRIN/ CAFFEINE	Butalbital Compound W/Codeine	oral	capsule	30-50-325-40	mg
CODEINE PHOSPHATE/BUTALBITAL/ASPIRIN/ CAFFEINE	Butalbital Compound-Codeine codeine-butalbital-ASA-caff	oral	capsule	30-50-325-40	mg
CODEINE PHOSPHATE/BUTALBITAL/ASPIRIN/ CAFFEINE	Fiorinal-Codeine #3	oral	capsule	30-50-325-40	mg
CODEINE PHOSPHATE/BUTALBITAL/ASPIRIN/ CAFFEINE	Fiortal/Codeine	oral	capsule	30-50-325-40	mg
CODEINE PHOSPHATE/BUTALBITAL/ASPIRIN/ CAFFEINE	Carisoprodol Compound- Codeine	oral	capsule	30-50-325-40	mg
CODEINE PHOSPHATE/BUTALBITAL/ASPIRIN/ CAFFEINE	carisoprodol-ASA-codeine	oral	tablet	200-325-16	mg
CODEINE PHOSPHATE/BUTALBITAL/ASPIRIN/ CAFFEINE	Soma Compound with Codeine	oral	tablet	200-325-16	mg
CODEINE PHOSPHATE/CARISOPRODOL/ASPIRIN	codeine sulfate	oral	tablet	200-325-16	mg
CODEINE SULFATE	codeine sulfate	oral	tablet	15	mg
CODEINE SULFATE	codeine sulfate	oral	solution	15 mg/2.5 mL	(2.5 mL)
CODEINE SULFATE	codeine sulfate	oral	tablet	30	mg
CODEINE SULFATE	codeine sulfate	oral	solution	30	mg/5 mL
CODEINE SULFATE	codeine sulfate	oral	solution	30 mg/5 mL	(5 mL)
CODEINE SULFATE	codeine sulfate	oral	tablet	60	mg
CODEINE/ASPIRIN/SALICYLAMIDE/ACETAMINOPHEN/CA FFEINE	Rid-A-Pain	oral	tablet		
CODEINE/ASPIRIN/SALICYLAMIDE/ACETAMINOPHEN/CA FFEINE	Rid-A-Pain W/Codeine	oral	tablet	227-97-32-32-1	mg
DIHYDROCODEINE BITARTRATE/ACETAMINOPHEN/ CAFFEINE	Trezix	oral	capsule	16-320.5-30	mg
DIHYDROCODEINE BITARTRATE/ACETAMINOPHEN/CAFFEINE	DHC Plus	oral	capsule	16-356.4-30	mg

Generic Name	Brand Name	Route	Form	Strength	Unit
DIHYDROCODEINE	Panlor DC				
BITARTRATE/ACETAMINOPHEN/CAFFEINE		oral	capsule	16-356.4-30	mg
DIHYDROCODEINE	Trezix				
BITARTRATE/ACETAMINOPHEN/CAFFEINE		oral	capsule	16-356.4-30	mg
DIHYDROCODEINE	dihydrocode-acetaminophen-				
BITARTRATE/ACETAMINOPHEN/CAFFEINE	caff	oral	tablet	32-712.8-60	mg
DIHYDROCODEINE	Panlor SS				
BITARTRATE/ACETAMINOPHEN/CAFFEINE		oral	tablet	32-712.8-60	mg
DIHYDROCODEINE	Zerlor				
BITARTRATE/ACETAMINOPHEN/CAFFEINE		oral	tablet	32-712.8-60	mg
DIHYDROCODEINE BITARTRATE/ASPIRIN/CAFFEINE	dihydrocodeine-aspirin-caff	oral	capsule	16-356.4-30	mg
DIHYDROCODEINE BITARTRATE/ASPIRIN/CAFFEINE	Synalgos-DC	oral	capsule	16-356.4-30	mg
DIHYDROCODEINE/ASPIRIN/CAFFEINE	Synalgos-DC	oral	capsule		
HYDROCODONE BITARTRATE/ACETAMINOPHEN	Stagesic-10	oral	tablet	10-250	mg
HYDROCODONE BITARTRATE/ACETAMINOPHEN	hydrocodone-acetaminophen	oral	tablet	10-300	mg
HYDROCODONE BITARTRATE/ACETAMINOPHEN	Vicodin HP	oral	tablet	10-300	mg
HYDROCODONE BITARTRATE/ACETAMINOPHEN	Xodol 10/300	oral	tablet	10-300	mg
HYDROCODONE BITARTRATE/ACETAMINOPHEN	Lortab Elixir	oral	solution	10-300	mg/15 mL
HYDROCODONE BITARTRATE/ACETAMINOPHEN	Zolvit	oral	solution	10-300	mg/15 mL
HYDROCODONE BITARTRATE/ACETAMINOPHEN	hydrocodone-acetaminophen	oral	tablet	10-325	mg
HYDROCODONE BITARTRATE/ACETAMINOPHEN	Lorcet HD	oral	tablet	10-325	mg
HYDROCODONE BITARTRATE/ACETAMINOPHEN	Lortab 10-325	oral	tablet	10-325	mg
HYDROCODONE BITARTRATE/ACETAMINOPHEN	Norco	oral	tablet	10-325	mg
HYDROCODONE BITARTRATE/ACETAMINOPHEN	Zamicet	oral	solution	10-325	mg/15 mL
HYDROCODONE BITARTRATE/ACETAMINOPHEN	hydrocodone-acetaminophen	oral	solution	10-325	mg/15 mL(15 mL)
HYDROCODONE BITARTRATE/ACETAMINOPHEN	Zydone	oral	tablet	10-400	mg
HYDROCODONE BITARTRATE/ACETAMINOPHEN	hydrocodone-acetaminophen	oral	tablet	10-500	mg
HYDROCODONE BITARTRATE/ACETAMINOPHEN	Lortab	oral	tablet	10-500	mg
HYDROCODONE BITARTRATE/ACETAMINOPHEN	Hycomed	oral	tablet	10-650	mg

Generic Name	Brand Name	Route	Form	Strength	Unit
HYDROCODONE BITARTRATE/ACETAMINOPHEN	hydrocodone-acetaminophen	oral	tablet	10-650	mg
HYDROCODONE BITARTRATE/ACETAMINOPHEN	Lorcet 10/650	oral	tablet	10-650	mg
HYDROCODONE BITARTRATE/ACETAMINOPHEN	Anexsia	oral	tablet	10-660	mg
HYDROCODONE BITARTRATE/ACETAMINOPHEN	hydrocodone-acetaminophen	oral	tablet	10-660	mg
HYDROCODONE BITARTRATE/ACETAMINOPHEN	Vicodin HP	oral	tablet	10-660	mg
HYDROCODONE BITARTRATE/ACETAMINOPHEN	hydrocodone-acetaminophen	oral	tablet	10-750	mg
HYDROCODONE BITARTRATE/ACETAMINOPHEN	Maxidone	oral	tablet	10-750	mg
HYDROCODONE BITARTRATE/ACETAMINOPHEN	hydrocodone-acetaminophen	oral	elixir	2.5-167	mg/5 mL
HYDROCODONE BITARTRATE/ACETAMINOPHEN	hydrocodone-acetaminophen	oral	solution	2.5-167	mg/5 mL
HYDROCODONE BITARTRATE/ACETAMINOPHEN	Lortab	oral	elixir	2.5-167	mg/5 mL
HYDROCODONE BITARTRATE/ACETAMINOPHEN	hydrocodone-acetaminophen	oral	tablet	2.5-325	mg
HYDROCODONE BITARTRATE/ACETAMINOPHEN	Verdrocet	oral	tablet	2.5-325	mg
HYDROCODONE BITARTRATE/ACETAMINOPHEN	hydrocodone-acetaminophen	oral	tablet	2.5-500	mg
HYDROCODONE BITARTRATE/ACETAMINOPHEN	Lortab	oral	tablet	2.5-500	mg
HYDROCODONE BITARTRATE/ACETAMINOPHEN	Liquicet	oral	solution	3.33-167	mg/5 mL
HYDROCODONE BITARTRATE/ACETAMINOPHEN	hydrocodone-acetaminophen	oral	solution	5-163	mg/7.5mL(7.5mL)
HYDROCODONE BITARTRATE/ACETAMINOPHEN	hydrocodone-acetaminophen	oral	tablet	5-300	mg
HYDROCODONE BITARTRATE/ACETAMINOPHEN	Vicodin	oral	tablet	5-300	mg
HYDROCODONE BITARTRATE/ACETAMINOPHEN	Xodol 5/300	oral	tablet	5-300	mg
HYDROCODONE BITARTRATE/ACETAMINOPHEN	Anexsia	oral	tablet	5-325	mg
HYDROCODONE BITARTRATE/ACETAMINOPHEN	hydrocodone-acetaminophen	oral	tablet	5-325	mg
HYDROCODONE BITARTRATE/ACETAMINOPHEN	Lorcet (hydrocodone)	oral	tablet	5-325	mg
HYDROCODONE BITARTRATE/ACETAMINOPHEN	Lortab 5-325	oral	tablet	5-325	mg
HYDROCODONE BITARTRATE/ACETAMINOPHEN	Norco	oral	tablet	5-325	mg

Generic Name	Brand Name	Route	Form	Strength	Unit
HYDROCODONE BITARTRATE/ACETAMINOPHEN	Procet	oral	tablet	5-325	mg
HYDROCODONE BITARTRATE/ACETAMINOPHEN	hydrocodone-acetaminophen	oral	solution	5-334	mg/10 mL
HYDROCODONE BITARTRATE/ACETAMINOPHEN	Zydone	oral	tablet	5-400	mg
HYDROCODONE BITARTRATE/ACETAMINOPHEN	Anexsia	oral	tablet	5-500	mg
HYDROCODONE BITARTRATE/ACETAMINOPHEN	Bancap HC	oral	capsule	5-500	mg
HYDROCODONE BITARTRATE/ACETAMINOPHEN	Ceta Plus	oral	capsule	5-500	mg
HYDROCODONE BITARTRATE/ACETAMINOPHEN	Co-Gesic	oral	tablet	5-500	mg
HYDROCODONE BITARTRATE/ACETAMINOPHEN	Dolacet	oral	capsule	5-500	mg
HYDROCODONE BITARTRATE/ACETAMINOPHEN	Dolorex Forte	oral	capsule	5-500	mg
HYDROCODONE BITARTRATE/ACETAMINOPHEN	Duocet	oral	tablet	5-500	mg
HYDROCODONE BITARTRATE/ACETAMINOPHEN	Hycomed	oral	tablet	5-500	mg
HYDROCODONE BITARTRATE/ACETAMINOPHEN	Hydrocet	oral	capsule	5-500	mg
HYDROCODONE BITARTRATE/ACETAMINOPHEN	hydrocodone-acetaminophen	oral	tablet	5-500	mg
HYDROCODONE BITARTRATE/ACETAMINOPHEN	hydrocodone-acetaminophen	oral	capsule	5-500	mg
HYDROCODONE BITARTRATE/ACETAMINOPHEN	Hydrogesic	oral	capsule	5-500	mg
HYDROCODONE BITARTRATE/ACETAMINOPHEN	Hy-Phen	oral	tablet	5-500	mg
HYDROCODONE BITARTRATE/ACETAMINOPHEN	Lorcet HD	oral	capsule	5-500	mg
HYDROCODONE BITARTRATE/ACETAMINOPHEN	Lortab	oral	tablet	5-500	mg
HYDROCODONE BITARTRATE/ACETAMINOPHEN	Margesic-H	oral	capsule	5-500	mg
HYDROCODONE BITARTRATE/ACETAMINOPHEN	Polygesic	oral	capsule	5-500	mg
HYDROCODONE BITARTRATE/ACETAMINOPHEN	Stagesic	oral	capsule	5-500	mg
HYDROCODONE BITARTRATE/ACETAMINOPHEN	Vanacet	oral	tablet	5-500	mg
HYDROCODONE BITARTRATE/ACETAMINOPHEN	Vendone	oral	capsule	5-500	mg
HYDROCODONE BITARTRATE/ACETAMINOPHEN	Vicodin	oral	tablet	5-500	mg
HYDROCODONE BITARTRATE/ACETAMINOPHEN	hydrocodone-acetaminophen	oral	tablet	7.5-300	mg
HYDROCODONE BITARTRATE/ACETAMINOPHEN	Vicodin ES	oral	tablet	7.5-300	mg
HYDROCODONE BITARTRATE/ACETAMINOPHEN	Xodol 7.5/300	oral	tablet	7.5-300	mg
HYDROCODONE BITARTRATE/ACETAMINOPHEN	Anexsia	oral	tablet	7.5-325	mg

Generic Name	Brand Name	Route	Form	Strength	Unit
HYDROCODONE BITARTRATE/ACETAMINOPHEN	hydrocodone-acetaminophen	oral	tablet	7.5-325	mg
HYDROCODONE BITARTRATE/ACETAMINOPHEN	Lorcet Plus	oral	tablet	7.5-325	mg
HYDROCODONE BITARTRATE/ACETAMINOPHEN	Lortab 7.5-325	oral	tablet	7.5-325	mg
HYDROCODONE BITARTRATE/ACETAMINOPHEN	Norco	oral	tablet	7.5-325	mg
HYDROCODONE BITARTRATE/ACETAMINOPHEN	Procet	oral	tablet	7.5-325	mg
HYDROCODONE BITARTRATE/ACETAMINOPHEN	Hycet	oral	solution	7.5-325	mg/15 mL
HYDROCODONE BITARTRATE/ACETAMINOPHEN	hydrocodone-acetaminophen	oral	solution	7.5-325	mg/15 mL
HYDROCODONE BITARTRATE/ACETAMINOPHEN	Zydone	oral	tablet	7.5-400	mg
HYDROCODONE BITARTRATE/ACETAMINOPHEN	hydrocodone-acetaminophen	oral	tablet	7.5-500	mg
HYDROCODONE BITARTRATE/ACETAMINOPHEN	Lortab	oral	tablet	7.5-500	mg
HYDROCODONE BITARTRATE/ACETAMINOPHEN	hydrocodone-acetaminophen	oral	solution	7.5-500	mg/15 mL
HYDROCODONE BITARTRATE/ACETAMINOPHEN	Lortab Elixir	oral	solution	7.5-500	mg/15 mL
HYDROCODONE BITARTRATE/ACETAMINOPHEN	hydrocodone-acetaminophen	oral	solution	7.5-500	mg/15 mL(15 mL)
HYDROCODONE BITARTRATE/ACETAMINOPHEN	Anexsia	oral	tablet	7.5-650	mg
HYDROCODONE BITARTRATE/ACETAMINOPHEN	hydrocodone-acetaminophen	oral	tablet	7.5-650	mg
HYDROCODONE BITARTRATE/ACETAMINOPHEN	Lorcet Plus	oral	tablet	7.5-650	mg
HYDROCODONE BITARTRATE/ACETAMINOPHEN	hydrocodone-acetaminophen	oral	tablet	7.5-750	mg
HYDROCODONE BITARTRATE/ACETAMINOPHEN	Vicodin ES	oral	tablet	7.5-750	mg
HYDROCODONE BITARTRATE/ACETAMINOPHEN/DIETARY SUPPLEMENT #11	Theracodophen-325	oral	combo pack	10-325	mg
HYDROCODONE BITARTRATE/ACETAMINOPHEN/DIETARY SUPPLEMENT #11	Theracodophen-650	oral	combo pack	10-650	mg
HYDROCODONE BITARTRATE/ACETAMINOPHEN/DIETARY SUPPLEMENT #11	Theracodophen-Low-90	oral	combo pack	5-500	mg

Generic Name	Brand Name	Route	Form	Strength	Unit
HYDROCODONE BITARTRATE/ASPIRIN	Alor	oral	tablet	5-500	mg
HYDROCODONE BITARTRATE/ASPIRIN	Damason-P	oral	tablet	5-500	mg
HYDROCODONE BITARTRATE/ASPIRIN	Lortab ASA	oral	tablet	5-500	mg
HYDROCODONE/IBUPROFEN	hydrocodone-ibuprofen	oral	tablet	10-200	mg
HYDROCODONE/IBUPROFEN	Ibudone	oral	tablet	10-200	mg
HYDROCODONE/IBUPROFEN	Reprexain	oral	tablet	10-200	mg
HYDROCODONE/IBUPROFEN	Xylon 10	oral	tablet	10-200	mg
HYDROCODONE/IBUPROFEN	hydrocodone-ibuprofen	oral	tablet	2.5-200	mg
HYDROCODONE/IBUPROFEN	Reprexain	oral	tablet	2.5-200	mg
HYDROCODONE/IBUPROFEN	hydrocodone-ibuprofen	oral	tablet	5-200	mg
HYDROCODONE/IBUPROFEN	Ibudone	oral	tablet	5-200	mg
HYDROCODONE/IBUPROFEN	Reprexain	oral	tablet	5-200	mg
HYDROCODONE/IBUPROFEN	hydrocodone-ibuprofen	oral	tablet	7.5-200	mg
HYDROCODONE/IBUPROFEN	Reprexain	oral	tablet	7.5-200	mg
HYDROCODONE/IBUPROFEN	Vicoprofen	oral	tablet	7.5-200	mg
HYDROMORPHONE HCL	Dilaudid	oral	liquid	1	mg/mL
HYDROMORPHONE HCL	Dilaudid-5	oral	liquid	1	mg/mL
HYDROMORPHONE HCL	hydromorphone	oral	liquid	1	mg/mL
HYDROMORPHONE HCL	Dilaudid	oral	tablet	2	mg
HYDROMORPHONE HCL	hydromorphone	oral	tablet	2	mg
HYDROMORPHONE HCL	Dilaudid	oral	tablet	4	mg
HYDROMORPHONE HCL	hydromorphone	oral	tablet	4	mg
HYDROMORPHONE HCL	Dilaudid	oral	tablet	8	mg
HYDROMORPHONE HCL	hydromorphone	oral	tablet	8	mg
IBUPROFEN/OXYCODONE HCL	Combunox	oral	tablet	400-5	mg
IBUPROFEN/OXYCODONE HCL	ibuprofen-oxycodone	oral	tablet	400-5	mg
LEVOMETHADYL ACETATE HCL	Orlaam	oral	solution	10	mg/mL
LEVORPHANOL TARTRATE	Levo-Dromoran	oral	tablet	2	mg
LEVORPHANOL TARTRATE	levorphanol tartrate	oral	tablet	2	mg
MEPERIDINE HCL	Demerol	oral	tablet	100	mg
MEPERIDINE HCL	meperidine	oral	tablet	100	mg
MEPERIDINE HCL	Meperitab	oral	tablet	100	mg
MEPERIDINE HCL	Demerol	oral	tablet	50	mg

Generic Name	Brand Name	Route	Form	Strength	Unit
MEPERIDINE HCL	meperidine	oral	tablet	50	mg
MEPERIDINE HCL	Meperitab	oral	tablet	50	mg
MEPERIDINE HCL	Demerol	oral	solution	50	mg/5 mL
MEPERIDINE HCL	meperidine	oral	solution	50	mg/5 mL
MORPHINE SULFATE	morphine concentrate	oral	solution	10	mg/0.5 mL
MORPHINE SULFATE	morphine	oral	solution	10	mg/5 mL
MORPHINE SULFATE	MSir	oral	solution	10	mg/5 mL
MORPHINE SULFATE	morphine concentrate	oral	solution	100 mg/5 mL	(20 mg/mL)
MORPHINE SULFATE	MSir Concentrate	oral	solution	100 mg/5 mL	(20 mg/mL)
MORPHINE SULFATE	Roxanol Concentrate	oral	solution	100 mg/5 mL	(20 mg/mL)
MORPHINE SULFATE	Roxanol-T Concentrate	oral	solution	100 mg/5 mL	(20 mg/mL)
MORPHINE SULFATE	morphine	oral	tablet	15	mg
MORPHINE SULFATE	MSir	oral	capsule	15	mg
MORPHINE SULFATE	MSir	oral	tablet	15	mg
MORPHINE SULFATE	morphine	oral	solution	20	mg/5 mL
MORPHINE SULFATE	MSir	oral	solution	20	mg/5 mL
MORPHINE SULFATE	morphine concentrate	oral	syringe	20	mg/mL
MORPHINE SULFATE	morphine	oral	tablet	30	mg
MORPHINE SULFATE	MSir	oral	tablet	30	mg
MORPHINE SULFATE	MSir	oral	capsule	30	mg
MORPHINE SULFATE	morphine concentrate	oral	solution	5	mg/0.25 mL
OPIUM TINCTURE	opium tincture	oral	tincture	10 mg/mL	(morphine)
OPIUM TINCTURE	opium tincture	oral	syringe	10 mg/mL	(morphine)
OXYCODONE HCL	Dazidox	oral	tablet	10	mg
OXYCODONE HCL	oxycodone	oral	tablet	10	mg
OXYCODONE HCL	oxycodone	oral	tablet	15	mg
OXYCODONE HCL	Roxicodone	oral	tablet	15	mg
OXYCODONE HCL	Dazidox	oral	tablet	20	mg
OXYCODONE HCL	oxycodone	oral	tablet	20	mg
OXYCODONE HCL	ETH-Oxydose	oral	concentrate	20	mg/mL
OXYCODONE HCL	oxycodone	oral	concentrate	20	mg/mL
OXYCODONE HCL	Oxyfast	oral	concentrate	20	mg/mL
OXYCODONE HCL	Roxicodone Intensol	oral	concentrate	20	mg/mL

Generic Name	Brand Name	Route	Form	Strength	Unit
OXYCODONE HCL	ETH-Oxydose	oral	concentrate	20	mg/mL (1 mL)
OXYCODONE HCL	oxycodone	oral	tablet	30	mg
OXYCODONE HCL	Roxicodone	oral	tablet	30	mg
OXYCODONE HCL	Endocodone	oral	tablet	5	mg
OXYCODONE HCL	Oxecta	oral	tablet, oral only	5	mg
OXYCODONE HCL	oxycodone	oral	tablet	5	mg
OXYCODONE HCL	oxycodone	oral	capsule	5	mg
OXYCODONE HCL	OxylR	oral	capsule	5	mg
OXYCODONE HCL	Percolone	oral	tablet	5	mg
OXYCODONE HCL	Roxicodone	oral	tablet	5	mg
OXYCODONE HCL	oxycodone	oral	solution	5	mg/5 mL
OXYCODONE HCL	Roxicodone	oral	solution	5	mg/5 mL
OXYCODONE HCL	Oxecta	oral	tablet, oral only	7.5	mg
OXYCODONE HCL/ACETAMINOPHEN	Lynox	oral	tablet	10-300	mg
OXYCODONE HCL/ACETAMINOPHEN	Perloxx	oral	tablet	10-300	mg
OXYCODONE HCL/ACETAMINOPHEN	Primlev	oral	tablet	10-300	mg
OXYCODONE HCL/ACETAMINOPHEN	Endocet	oral	tablet	10-325	mg
OXYCODONE HCL/ACETAMINOPHEN	oxycodone-acetaminophen	oral	tablet	10-325	mg
OXYCODONE HCL/ACETAMINOPHEN	Percocet	oral	tablet	10-325	mg
OXYCODONE HCL/ACETAMINOPHEN	Magnacet	oral	tablet	10-400	mg
OXYCODONE HCL/ACETAMINOPHEN	ALCET	oral	tablet	10-500	mg
OXYCODONE HCL/ACETAMINOPHEN	Narvox	oral	tablet	10-500	mg
OXYCODONE HCL/ACETAMINOPHEN	Xolox	oral	tablet	10-500	mg
OXYCODONE HCL/ACETAMINOPHEN	Endocet	oral	tablet	10-650	mg
OXYCODONE HCL/ACETAMINOPHEN	oxycodone-acetaminophen	oral	tablet	10-650	mg
OXYCODONE HCL/ACETAMINOPHEN	Percocet	oral	tablet	10-650	mg
OXYCODONE HCL/ACETAMINOPHEN	Lynox	oral	tablet	2.5-300	mg
OXYCODONE HCL/ACETAMINOPHEN	Perloxx	oral	tablet	2.5-300	mg
OXYCODONE HCL/ACETAMINOPHEN	Primalev	oral	tablet	2.5-300	mg
OXYCODONE HCL/ACETAMINOPHEN	Endocet	oral	tablet	2.5-325	mg
OXYCODONE HCL/ACETAMINOPHEN	oxycodone-acetaminophen	oral	tablet	2.5-325	mg
OXYCODONE HCL/ACETAMINOPHEN	Percocet	oral	tablet	2.5-325	mg
OXYCODONE HCL/ACETAMINOPHEN	Magnacet	oral	tablet	2.5-400	mg

Generic Name	Brand Name	Route	Form	Strength	Unit
OXYCODONE HCL/ACETAMINOPHEN	Lynox	oral	tablet	5-300	mg
OXYCODONE HCL/ACETAMINOPHEN	Perloxx	oral	tablet	5-300	mg
OXYCODONE HCL/ACETAMINOPHEN	Primlev	oral	tablet	5-300	mg
OXYCODONE HCL/ACETAMINOPHEN	Endocet	oral	tablet	5-325	mg
OXYCODONE HCL/ACETAMINOPHEN	oxycodone-acetaminophen	oral	tablet	5-325	mg
OXYCODONE HCL/ACETAMINOPHEN	Percocet	oral	tablet	5-325	mg
OXYCODONE HCL/ACETAMINOPHEN	Roxicet	oral	tablet	5-325	mg
OXYCODONE HCL/ACETAMINOPHEN	oxycodone-acetaminophen	oral	solution	5-325	mg/5 mL
OXYCODONE HCL/ACETAMINOPHEN	Roxicet	oral	solution	5-325	mg/5 mL
OXYCODONE HCL/ACETAMINOPHEN	Magnacet	oral	tablet	5-400	mg
OXYCODONE HCL/ACETAMINOPHEN	oxycodone-acetaminophen	oral	capsule	5-500	mg
OXYCODONE HCL/ACETAMINOPHEN	Roxicet	oral	tablet	5-500	mg
OXYCODONE HCL/ACETAMINOPHEN	Tylox	oral	capsule	5-500	mg
OXYCODONE HCL/ACETAMINOPHEN	Lynox	oral	tablet	7.5-300	mg
OXYCODONE HCL/ACETAMINOPHEN	Perloxx	oral	tablet	7.5-300	mg
OXYCODONE HCL/ACETAMINOPHEN	Primlev	oral	tablet	7.5-300	mg
OXYCODONE HCL/ACETAMINOPHEN	Endocet	oral	tablet	7.5-325	mg
OXYCODONE HCL/ACETAMINOPHEN	oxycodone-acetaminophen	oral	tablet	7.5-325	mg
OXYCODONE HCL/ACETAMINOPHEN	Percocet	oral	tablet	7.5-325	mg
OXYCODONE HCL/ACETAMINOPHEN	Xartemis XR	oral	tab,oral only,IR & ER, biphas	7.5-325	mg
OXYCODONE HCL/ACETAMINOPHEN	Magnacet	oral	tablet	7.5-400	mg
OXYCODONE HCL/ACETAMINOPHEN	Endocet	oral	tablet	7.5-500	mg
OXYCODONE HCL/ACETAMINOPHEN	oxycodone-acetaminophen	oral	tablet	7.5-500	mg
OXYCODONE HCL/ACETAMINOPHEN	Percocet	oral	tablet	7.5-500	mg
OXYCODONE HCL/ASPIRIN	Endodan	oral	tablet	4.8355-325	mg
OXYCODONE HCL/ASPIRIN	oxycodone-aspirin	oral	tablet	4.8355-325	mg
OXYCODONE HCL/ASPIRIN	Percodan	oral	tablet	4.8355-325	mg
OXYCODONE HCL/OXYCODONE					
TEREPHTHALATE/ASPIRIN	Endodan (Old Formula)	oral	tablet	4.5-0.38-325	mg
OXYCODONE HCL/OXYCODONE	oxycodone HCl-oxycodone-				
TEREPHTHALATE/ASPIRIN	ASA	oral	tablet	4.5-0.38-325	mg
OXYCODONE HCL/OXYCODONE					
TEREPHTHALATE/ASPIRIN	Percodan	oral	tablet	4.5-0.38-325	mg

Generic Name	Brand Name	Route	Form	Strength	Unit
OXYCODONE/ASPIRIN	Percodan Demi	oral	tablet	2.44-325	mg
OXYMORPHONE HCL	Opana	oral	tablet	10	mg
OXYMORPHONE HCL	oxymorphone	oral	tablet	10	mg
OXYMORPHONE HCL	Opana	oral	tablet	5	mg
OXYMORPHONE HCL	oxymorphone	oral	tablet	5	mg
PROPOXYPHENE HCL	Darvon	oral	capsule	65	mg
PROPOXYPHENE HCL	PP-Cap	oral	capsule	65	mg
PROPOXYPHENE HCL	propoxyphene	oral	capsule	65	mg
PROPOXYPHENE HCL/ACETAMINOPHEN	propoxyphene-acetaminophen	oral	tablet	65-650	mg
PROPOXYPHENE HCL/ACETAMINOPHEN	Wygesic	oral	tablet	65-650	mg
PROPOXYPHENE HCL/ASPIRIN/CAFFEINE	Darvon Compound 32	oral	capsule	32-389-32.4	mg
PROPOXYPHENE HCL/ASPIRIN/CAFFEINE	Darvon Compound-65	oral	capsule	65-389-32.4	mg
PROPOXYPHENE HCL/ASPIRIN/CAFFEINE	PC-Cap	oral	capsule	65-389-32.4	mg
PROPOXYPHENE HCL/ASPIRIN/CAFFEINE	Propoxyphene Compound-65	oral	capsule	65-389-32.4	mg
PROPOXYPHENE NAPSYLATE	Darvon-N	oral	tablet	100	mg
PROPOXYPHENE NAPSYLATE	propoxyphene napsylate	oral	tablet	100	mg
PROPOXYPHENE NAPSYLATE/ACETAMINOPHEN	Balacet 325	oral	tablet	100-325	mg
PROPOXYPHENE NAPSYLATE/ACETAMINOPHEN	propoxyphene N-acetaminophen	oral	tablet	100-325	mg
PROPOXYPHENE NAPSYLATE/ACETAMINOPHEN	Trycet	oral	tablet	100-325	mg
PROPOXYPHENE NAPSYLATE/ACETAMINOPHEN	Darvocet A500	oral	tablet	100-500	mg
PROPOXYPHENE NAPSYLATE/ACETAMINOPHEN	propoxyphene N-acetaminophen	oral	tablet	100-500	mg
PROPOXYPHENE NAPSYLATE/ACETAMINOPHEN	Darvocet-N 100	oral	tablet	100-650	mg
PROPOXYPHENE NAPSYLATE/ACETAMINOPHEN	Propoxacet-N 100	oral	tablet	100-650	mg
PROPOXYPHENE NAPSYLATE/ACETAMINOPHEN	propoxyphene N-acetaminophen	oral	tablet	100-650	mg
PROPOXYPHENE NAPSYLATE/ACETAMINOPHEN	Darvocet-N 50	oral	tablet	50-325	mg
PROPOXYPHENE NAPSYLATE/ACETAMINOPHEN	propoxyphene N-acetaminophen	oral	tablet	50-325	mg
TAPENTADOL HCL	Nucynta	oral	tablet	100	mg

Generic Name	Brand Name	Route	Form	Strength	Unit
TAPENTADOL HCL	Nucynta	oral	tablet	50	mg
TAPENTADOL HCL	Nucynta	oral	tablet	75	mg
TRAMADOL HCL	ConZip	oral	capsule,ER biphasic 24 hr 25-75	100	mg
TRAMADOL HCL	Ryzolt	oral	tablet, ER multiphase 24 hr	100	mg
TRAMADOL HCL	tramadol	oral	tablet extended release 24 hr	100	mg
TRAMADOL HCL	tramadol	oral	tablet, ER multiphase 24 hr	100	mg
TRAMADOL HCL	Ultram ER	oral	tablet extended release 24 hr	100	mg
TRAMADOL HCL	tramadol	oral	capsule,ER biphasic 24 hr 25-75	150	mg
TRAMADOL HCL	ConZip	oral	capsule,ER biphasic 24 hr 25-75	200	mg
TRAMADOL HCL	Ryzolt	oral	tablet, ER multiphase 24 hr	200	mg
TRAMADOL HCL	tramadol	oral	tablet extended release 24 hr	200	mg
TRAMADOL HCL	tramadol	oral	tablet, ER multiphase 24 hr	200	mg
TRAMADOL HCL	Ultram ER	oral	tablet extended release 24 hr	200	mg
TRAMADOL HCL	ConZip	oral	capsule,ER biphasic 24 hr 17-83	300	mg
TRAMADOL HCL	Ryzolt	oral	tablet, ER multiphase 24 hr	300	mg
TRAMADOL HCL	tramadol	oral	tablet, ER multiphase 24 hr	300	mg
TRAMADOL HCL	tramadol	oral	tablet extended release 24 hr	300	mg
TRAMADOL HCL	Ultram ER	oral	tablet extended release 24 hr	300	mg
TRAMADOL HCL	Rybix ODT	oral	tablet,disintegrating	50	mg
TRAMADOL HCL	tramadol	oral	tablet	50	mg
TRAMADOL HCL	Ultram	oral	tablet	50	mg
TRAMADOL HCL/ACETAMINOPHEN	tramadol-acetaminophen	oral	tablet	37.5-325	mg
TRAMADOL HCL/ACETAMINOPHEN	Ultracet	oral	tablet	37.5-325	mg
TRAMADOL HCL/DIETARY SUPPLEMENT,MISC. CB.11	Theratramadol-60	oral	combo pack	50	mg
TRAMADOL HCL/DIETARY SUPPLEMENT,MISC. CB.11	Theratramadol-90	oral	combo pack	50	mg
TRAMADOL HCL/GLUCOSAMINE SULFATE	Synapryn	oral	suspension for reconstitution	10-5	mg/mL

Appendix D: Specifications for TO16_CAP_MPL1R_wp022_NSDP_V01

The Opioid Analgesics Prescribing Trends Workgroup has requested the use of the Cohort Identification and Descriptive Analysis (CIDA) Tool, version 2.0.7, to investigate opioid use and drug screen metrics in the Mini-Sentinel Distributed Database (MSDD). The query period was from January 1, 2009 to December 31, 2013, and the enrollment gap was set at 45 days. Age groups were split as follows: 0-11, 12-17, 18-24, 25-34, 35-44, 45-54, 55-64. In total, 48 scenarios were examined. *This report contains results for scenarios 1-24 only. Results for scenarios 25-48 are contained in Report 2.*

Enrollment Gap	45 days
Age Groups	0-11, 12-17, 18-24, 25-34, 35-44, 45-54, 55-64
Query Period	1/1/2009 - 12/31/2013
Coverage Requirement	Drug and Medical Coverage
Same Day Dispensing Processing	Maximum days supplied, Add amount supplied
Stockpiling Grouping	Generic name and dose

Scenario	Pre-exposure Enrollment Requirement	Drug/Exposure		Drug/Exposure						Inclusion/Exclusion Criteria				Event/Outcome
		Incident exposure	Incident w/ respect to:	Washout (days)	Cohort Definition	Minimum Episode Duration	Minimum Days Supplied	Episode Gap	Episode Extension Period	Inclusion/Exclusion Condition	Include or Exclude	Lookback Start	Lookback End	Event/Outcome
1	183	ER/LA opioid analgesics	ER/LA opioid analgesics	183	02	1	1	10	0	Opioid poisoning	Exclude	-183	-1	Dummy
2	183	ER/LA opioid analgesics	ER/LA opioid analgesics	183	02	1	1	10	0	Opioid poisoning IR opioid use	Exclude Exclude	-183 -60	-1 -1	Dummy
3	183	ER/LA opioid analgesics	ER/LA opioid analgesics	183	02	1	1	10	0	Opioid poisoning Drug screen	Exclude Include	-183 -30	-1 0	Dummy
4	183	ER/LA opioid analgesics	ER/LA opioid analgesics	183	02	1	1	10	0	Opioid poisoning IR opioid use Drug screen	Exclude Exclude Include	-183 -60 -30	-1 -1 0	Dummy
5	183	ER/LA opioid analgesics	ER/LA opioid analgesics	183	02	1	1	10	0	Opioid poisoning Drug screen	Exclude Include	-183 1	-1 183	Dummy
6	183	ER/LA opioid analgesics	ER/LA opioid analgesics	183	02	1	1	10	0	Opioid poisoning IR opioid use Drug screen	Exclude Exclude Include	-183 -60 1	-1 -1 183	Dummy
7	183	ER/LA opioid analgesics	ER/LA opioid analgesics	183	02	84	84	10	0	Opioid poisoning	Exclude	-183	-1	Dummy
8	183	ER/LA opioid analgesics	ER/LA opioid analgesics	183	02	84	84	10	0	Opioid poisoning IR opioid use	Exclude Exclude	-183 -60	-1 -1	Dummy
9	183	ER/LA opioid analgesics	ER/LA opioid analgesics	183	02	84	84	10	0	Opioid poisoning Drug screen	Exclude Include	-183 -30	-1 0	Dummy
10	183	ER/LA opioid analgesics	ER/LA opioid analgesics	183	02	84	84	10	0	Opioid poisoning IR opioid use Drug screen	Exclude Exclude Include	-183 -60 -30	-1 -1 0	Dummy

11	183	ER/LA opioid analgesics	ER/LA opioid analgesics	183	02	84	84	10	0	Opioid poisoning	Exclude	-183	-1	Dummy
										Drug screen	Include	1	183	
12	183	ER/LA opioid analgesics	ER/LA opioid analgesics	183	02	84	84	10	0	Opioid poisoning	Exclude	-183	-1	Dummy
										IR opioid use	Exclude	-60	-1	
										Drug screen	Include	1	183	
13	90	ER/LA opioid analgesics	ER/LA opioid analgesics	90	02	1	1	10	0	Opioid poisoning	Exclude	-90	-1	Dummy
14	90	ER/LA opioid analgesics	ER/LA opioid analgesics	90	02	1	1	10	0	Opioid poisoning	Exclude	-90	-1	Dummy
										IR opioid use	Exclude	-60	-1	
15	90	ER/LA opioid analgesics	ER/LA opioid analgesics	90	02	1	1	10	0	Opioid poisoning	Exclude	-90	-1	Dummy
										Drug screen	Include	-30	0	
16	90	ER/LA opioid analgesics	ER/LA opioid analgesics	90	02	1	1	10	0	Opioid poisoning	Exclude	-90	-1	Dummy
										IR opioid use	Exclude	-60	-1	
										Drug screen	Include	-30	0	
17	90	ER/LA opioid analgesics	ER/LA opioid analgesics	90	02	1	1	10	0	Opioid poisoning	Exclude	-90	-1	Dummy
										Drug screen	Include	1	183	
18	90	ER/LA opioid analgesics	ER/LA opioid analgesics	90	02	1	1	10	0	Opioid poisoning	Exclude	-90	-1	Dummy
										IR opioid use	Exclude	-60	-1	
										Drug screen	Include	1	183	
19	90	ER/LA opioid analgesics	ER/LA opioid analgesics	90	02	84	84	10	0	Opioid poisoning	Exclude	-90	-1	Dummy
20	90	ER/LA opioid analgesics	ER/LA opioid analgesics	90	02	84	84	10	0	Opioid poisoning	Exclude	-90	-1	Dummy
										IR opioid use	Exclude	-60	-1	
21	90	ER/LA opioid analgesics	ER/LA opioid analgesics	90	02	84	84	10	0	Opioid poisoning	Exclude	-90	-1	Dummy
										Drug screen	Include	-30	0	
22	90	ER/LA opioid analgesics	ER/LA opioid analgesics	90	02	84	84	10	0	Opioid poisoning	Exclude	-90	-1	Dummy
										IR opioid use	Exclude	-60	-1	
										Drug screen	Include	-30	0	
23	90	ER/LA opioid analgesics	ER/LA opioid analgesics	90	02	84	84	10	0	Opioid poisoning	Exclude	-90	-1	Dummy
										Drug screen	Include	1	183	
24	90	ER/LA opioid analgesics	ER/LA opioid analgesics	90	02	84	84	10	0	Opioid poisoning	Exclude	-90	-1	Dummy
										IR opioid use	Exclude	-60	-1	
										Drug screen	Include	1	183	
25	183	ERO opioid analgesics	ER/LA opioid analgesics	183	02	1	1	10	0	Opioid poisoning	Exclude	-183	-1	Dummy
26	183	ERO opioid analgesics	ER/LA opioid analgesics	183	02	1	1	10	0	Opioid poisoning	Exclude	-183	-1	Dummy
										IR opioid use	Exclude	-60	-1	
27	183	ERO opioid analgesics	ER/LA opioid analgesics	183	02	1	1	10	0	Opioid poisoning	Exclude	-183	-1	Dummy
										Drug screen	Include	-30	0	

28	183	ERO opioid analgesics	ER/LA opioid analgesics	183	02	1	1	10	0	Opioid poisoning	Exclude	-183	-1	Dummy
										IR opioid use	Exclude	-60	-1	
										Drug screen	Include	-30	0	
29	183	ERO opioid analgesics	ER/LA opioid analgesics	183	02	1	1	10	0	Opioid poisoning	Exclude	-183	-1	Dummy
										Drug screen	Include	1	183	
										Opioid poisoning	Exclude	-183	-1	
30	183	ERO opioid analgesics	ER/LA opioid analgesics	183	02	1	1	10	0	IR opioid use	Exclude	-60	-1	Dummy
										Drug screen	Include	1	183	
										Opioid poisoning	Exclude	-183	-1	
31	183	ERO opioid analgesics	ER/LA opioid analgesics	183	02	84	84	10	0	Opioid poisoning	Exclude	-183	-1	Dummy
32	183	ERO opioid analgesics	ER/LA opioid analgesics	183	02	84	84	10	0	Opioid poisoning	Exclude	-183	-1	Dummy
33	183	ERO opioid analgesics	ER/LA opioid analgesics	183	02	84	84	10	0	IR opioid use	Exclude	-60	-1	Dummy
										Drug screen	Include	-30	0	
										Opioid poisoning	Exclude	-183	-1	
34	183	ERO opioid analgesics	ER/LA opioid analgesics	183	02	84	84	10	0	IR opioid use	Exclude	-60	-1	Dummy
										Drug screen	Include	-30	0	
										Opioid poisoning	Exclude	-183	-1	
35	183	ERO opioid analgesics	ER/LA opioid analgesics	183	02	84	84	10	0	Drug screen	Include	1	183	Dummy
										Opioid poisoning	Exclude	-183	-1	
										IR opioid use	Exclude	-60	-1	
36	183	ERO opioid analgesics	ER/LA opioid analgesics	183	02	84	84	10	0	Drug screen	Include	1	183	Dummy
										Opioid poisoning	Exclude	-183	-1	
										IR opioid use	Exclude	-60	-1	
37	90	ERO opioid analgesics	ER/LA opioid analgesics	90	02	1	1	10	0	Opioid poisoning	Exclude	-90	-1	Dummy
38	90	ERO opioid analgesics	ER/LA opioid analgesics	90	02	1	1	10	0	IR opioid use	Exclude	-60	-1	Dummy
										Drug screen	Include	-30	0	
										Opioid poisoning	Exclude	-90	-1	
39	90	ERO opioid analgesics	ER/LA opioid analgesics	90	02	1	1	10	0	Drug screen	Include	-30	0	Dummy
										IR opioid use	Exclude	-60	-1	
										Opioid poisoning	Exclude	-90	-1	
40	90	ERO opioid analgesics	ER/LA opioid analgesics	90	02	1	1	10	0	Drug screen	Include	-30	0	Dummy
										IR opioid use	Exclude	-60	-1	
										Opioid poisoning	Exclude	-90	-1	
41	90	ERO opioid analgesics	ER/LA opioid analgesics	90	02	1	1	10	0	Drug screen	Include	1	183	Dummy
										IR opioid use	Exclude	-60	-1	
										Opioid poisoning	Exclude	-90	-1	
42	90	ERO opioid analgesics	ER/LA opioid analgesics	90	02	1	1	10	0	Drug screen	Include	1	183	Dummy
										IR opioid use	Exclude	-60	-1	
										Opioid poisoning	Exclude	-90	-1	
43	90	ERO opioid analgesics	ER/LA opioid analgesics	90	02	84	84	10	0	Opioid poisoning	Exclude	-90	-1	Dummy
44	90	ERO opioid analgesics	ER/LA opioid analgesics	90	02	84	84	10	0	IR opioid use	Exclude	-60	-1	Dummy
										Drug screen	Include	-30	0	
										Opioid poisoning	Exclude	-90	-1	
45	90	ERO opioid analgesics	ER/LA opioid analgesics	90	02	84	84	10	0	Drug screen	Include	-30	0	Dummy
										IR opioid use	Exclude	-60	-1	
										Opioid poisoning	Exclude	-90	-1	

46	90	ERO opioid analgesics	ER/LA opioid analgesics	90	02	84	84	10	0	Opioid poisoning	Exclude	-90	-1	Dummy
										IR opioid use	Exclude	-60	-1	
										Drug screen	Include	-30	0	
47	90	ERO opioid analgesics	ER/LA opioid analgesics	90	02	84	84	10	0	Opioid poisoning	Exclude	-90	-1	Dummy
										Drug screen	Include	1	183	
48	90	ERO opioid analgesics	ER/LA opioid analgesics	90	02	84	84	10	0	Opioid poisoning	Exclude	-90	-1	Dummy
										IR opioid use	Exclude	-60	-1	
										Drug screen	Include	1	183	

National Drug Codes (NDCs) checked against First Data Bank's "National Drug Data File (NDDF®) Plus"

International Classification of Diseases, Ninth Edition, Clinical Modification (ICD-9-CM) diagnosis and procedure codes checked against "Ingenix 2012 ICD-9-CM Data File" provided by OptumInsight

Healthcare Common Procedure Coding System (HCPCS) codes checked against "Optum 2012 HCPCS Level II Data File" provided by OptumInsight

Current Procedural Terminology, Fourth Revision (CPT-4) codes checked against "Optum 2012 Current Procedure Codes & Relative Values Data File" provided by OptumInsight

Appendix E: List of Dates of Available Data for Each Data Partner as of Request Send Date (July 29, 2015)

DP ID	Start Date	End Date
DP001	1/1/2009	12/31/2013
DP002	1/1/2009	12/31/2013
DP003	1/1/2009	12/31/2013
DP004	1/1/2009	12/31/2013
DP005	1/1/2009	12/31/2013
DP006	1/1/2009	12/31/2013
DP007	1/1/2009	12/31/2012
DP008	1/1/2009	12/31/2013
DP009	1/1/2009	12/31/2013
DP010	1/1/2009	12/31/2013
DP011	1/1/2009	12/31/2013
DP012	1/1/2009	12/31/2013
DP013	1/1/2009	6/30/2012
DP014	1/1/2009	12/31/2013
DP015	1/1/2009	12/31/2013